[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 175
1. Hiromura M, Suizu F, Narita M, Kinowaki K, Noguchi M: Identification of nerve growth factor-responsive element of the TCL1 promoter as a novel negative regulatory element. J Biol Chem; 2006 Sep 22;281(38):27753-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The serine/threonine kinase, Akt (protein kinase B) plays a central role in the regulation of intracellular cell survival.
  • Recently, we demonstrated that the proto-oncogene TCL1, overexpressed in human T-cell prolymphocytic leukemia, is an Akt kinase co-activator.
  • Nur77/NGFI-B, an orphan receptor superfamily transcription factor implicated in T-cell apoptosis, is a substrate for Akt.
  • In an electrophoretic mobility shift assay with chromosomal immunoprecipitation assays, wild-type Nur77, but not S350A mutant Nur77, could specifically bind to TCL1-NBRE.
  • To the best of our knowledge, TCL1-NBRE is the first direct target of Nur77 involving the regulation of intracellular cell death survival.

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835233.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / FOXO3 protein, human; 0 / Forkhead Transcription Factors; 0 / NR4A1 protein, human; 0 / Nr4a1 protein, mouse; 0 / Nr4a1 protein, rat; 0 / Nuclear Receptor Subfamily 4, Group A, Member 1; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / TCL1A protein, human; 0 / Transcription Factors; 9061-61-4 / Nerve Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


2. Shimizu D, Nomura K, Matsumoto Y, Nishida K, Taki T, Horiike S, Inaba T, Fujita N, Taniwaki M: Small cell variant type of T-prolymphocytic leukemia with a four-year indolent course preceding acute exacerbation. Leuk Lymphoma; 2006 Jun;47(6):1170-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell variant type of T-prolymphocytic leukemia with a four-year indolent course preceding acute exacerbation.
  • [MeSH-major] Leukemia, Prolymphocytic / diagnosis. Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / metabolism. CD8-Positive T-Lymphocytes / immunology. Fatal Outcome. Female. Humans. Immunophenotyping. Lymphocytes / metabolism. Middle Aged. Prognosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840216.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


3. Ho AD, Hensel M: Pentostatin and purine analogs for indolent lymphoid malignancies. Future Oncol; 2006 Apr;2(2):169-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pentostatin has been shown to be active in a variety of B- and T-cell malignancies.
  • Early clinical trials indicated that this agent was highly active in acute lymphoblastic leukemias with high intracellular adenosine deaminase levels.
  • Through the efforts of a few investigators, better tolerated, low-dose regimens have been shown to be extremely active in lymphoproliferative diseases with very low intracellular adenosine deaminase levels such as hairy cell leukemia, B- and T-cell chronic leukemias, T-cell cutaneous lymphomas and low-grade non-Hodgkin lymphomas.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Leukemia, Hairy Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Prolymphocytic / drug therapy. Pentostatin / therapeutic use. Purine Nucleosides / therapeutic use

  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16563086.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenosine Deaminase Inhibitors; 0 / Antibiotics, Antineoplastic; 0 / Purine Nucleosides; 395575MZO7 / Pentostatin
  • [Number-of-references] 92
  •  go-up   go-down


Advertisement
4. Naseem S, Gupta R, Kashyap R, Nityanand S: T-cell prolymphocytic leukemia: a report of two cases with review of literature. Indian J Hematol Blood Transfus; 2008 Dec;24(4):178-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: a report of two cases with review of literature.
  • T-cell Prolymphocytic Leukemia (T-PLL) is a mature post-thymic T-cell malignancy with aggressive clinical course.
  • The principal disease characteristics are organomegaly, skin lesions and raised lymphocyte counts.
  • T-PLL is a rare T-cell malignancy with characteristic clinical and laboratory features and a poor prognosis.
  • It needs to be differentiated from B-Cell prolymphocytic leukemia (B-PLL) and other mature T-cell lymphoproliferative disorders with predominant leukemic pattern.
  • Differentiation can be made by a comprehensive approach taking into account the clinical features, the cell morphology and the immunophenotype of leukemic cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Leukemia. 1990 Apr;4(4):262-6 [2366582.001]
  • [Cites] Blood. 1987 Oct;70(4):926-31 [3115337.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Br J Haematol. 1980 Jul;45(3):513-4 [6968583.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Surv Ophthalmol. 2004 Sep-Oct;49(5):525-36 [15325197.001]
  • [Cites] Lancet. 1973 Aug 4;2(7823):232-4 [4124423.001]
  • (PMID = 23100959.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3475431
  • [Keywords] NOTNLM ; Immunophenotyping / Prolymphocyte / T-PLL
  •  go-up   go-down


5. Noguchi M, Ropars V, Roumestand C, Suizu F: Proto-oncogene TCL1: more than just a coactivator for Akt. FASEB J; 2007 Aug;21(10):2273-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, the proto-oncogene TCL1 (T cell leukemia 1), with a previously unknown physiological function, was shown to interact with the Akt pleckstrin homology domain, enhancing Akt kinase activity; hence, it functions as an Akt kinase coactivator.
  • [MeSH-major] Leukemia, Prolymphocytic / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins c-akt / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17360849.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Number-of-references] 109
  •  go-up   go-down


6. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M: T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma; 2005 Nov;6(3):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: a single-institution experience.
  • BACKGROUND: T-cell prolymphocytic leukemia is an uncommon, aggressive, mature T-cell leukemia characterized by proliferation of T-cell lymphocytes.
  • The recent availability of modern immunophenotypic and molecular tools has allowed a better distinction of this disorder from its B-cell counterpart and other mature T-cell leukemias.
  • PATIENTS AND METHODS: The clinical, pathologic, and cytogenetic features of 57 patients with T-PLL who were evaluated at the Department of Leukemia, M. D.
  • RESULTS: The most common cytogenetic abnormality was inv(14)(q11;q32), which was present in 7 patients.
  • In all 7 patients, this abnormality was associated with other chromosomal aberrations.
  • CONCLUSION: Treatment with alemtuzumab results in higher response rates and a better survival rate in patients with T-cell prolymphocytic leukemia.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Leukemia, Prolymphocytic / metabolism. Proto-Oncogene Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Chromosome Inversion. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354329.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human
  •  go-up   go-down


7. Beck C, Humpe A, Harder S, Schmid M, Horst HA: Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT: two very rare conditions in one patient. Ann Hematol; 2005 Sep;84(9):616-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT: two very rare conditions in one patient.
  • We report a 36-year-old male with myeloid/natural killer (NK)-cell precursor acute leukaemia with a complex aberrant karyotype, who was treated according to an acute-myeloid-leukaemia (AML) treatment protocol (idarubicine, cytarabine, and etoposide) followed by high-dose cytarabine consolidation and achieved complete remission.
  • He underwent allogeneic matched unrelated donor (MUD) peripheral blood stem-cell transplantation (PBSCT) and remained in remission throughout his remaining life.
  • This patient represents one of the few cases published achieving remission for a significant period of time after being diagnosed with myeloid/NK-cell precursor acute leukaemia, a very rare malignant disease.
  • In addition, the development of a myelodysplastic syndrome of donor origin is extremely rare and only very few cases are published worldwide.
  • [MeSH-major] Killer Cells, Natural / pathology. Leukemia, Myeloid / pathology. Leukemia, Myeloid / therapy. Leukemia, Prolymphocytic, T-Cell / pathology. Myelodysplastic Syndromes / etiology. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Fatal Outcome. Humans. Infection. Male. Remission Induction / methods. Thrombocytopenia. Tissue Donors. Transplantation, Homologous. Treatment Outcome


8. Umehara F, Hagiwara T, Yoshimura M, Higashi K, Arimura K: Enlarged, multifocal upper limb neuropathy with HTLV-I associated myelopathy in a patient with chronic adult T-cell leukemia. J Neurol Sci; 2008 Mar 15;266(1-2):167-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enlarged, multifocal upper limb neuropathy with HTLV-I associated myelopathy in a patient with chronic adult T-cell leukemia.
  • The authors herein describe a case of multifocal peripheral neuropathy with HTLV-I-associated myelopathy (HAM) in a patient with chronic adult T-cell leukemia (ATL).
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / complications. Paraparesis, Tropical Spastic / complications. Peripheral Nervous System Diseases / etiology. Peripheral Nervous System Diseases / pathology. Upper Extremity / pathology
  • [MeSH-minor] Blood Cell Count. Contrast Media. Female. Fluorodeoxyglucose F18. Gadolinium. Humans. Magnetic Resonance Imaging. Middle Aged. Neural Conduction / physiology. Neurologic Examination. Peripheral Nerves / pathology. Peripheral Nerves / physiopathology. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096188.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


9. Kardum-Skelin I, Planinc-Peraica A, Ostojić Kolonić S, Radić-Kristo D, Milas M, Vrhovac R, Sustercić D, Minigo H, Jaksić B: [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases]. Acta Med Croatica; 2008 Oct;62(4):351-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis was performed in the overall CLLPD population and separately in a subgroup of patients with B chronic lymphocytic leukemia with variants (B-CLL+V) including typical B chronic lymphocytic leukemia (B-CLL), mixed chronic lymphocytic leukemia and prolymphocytic leukemia (CLL/PLL), and a variant of chronic lymphocytic leukemia with lymphoplasmocytoid differentiation (CLL/IMC).
  • Poorer disease outcome was associated with interstitial and nodular infiltration found on bone biopsy.
  • Poorer prognosis was associated with red blood cell count <2.5 x 10(12)/L, leukocyte count >100 x 10(9)/L, reticulocyte count >5/10(3) E, hemoglobin <100 g/L and iron <15 mol/L.
  • CONCLUSION: Careful clinical examination is an important step on assessing the extent and progression of the disease, and a major chain on tailoring individualized therapeutic approach, along with clinical stages according to Rai and Binet, CLLPD subtype and progression factors (DTM and DTL).
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Prolymphocytic / pathology. Lymphoproliferative Disorders / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205412.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


10. de la Fuente C, Gupta MV, Klase Z, Strouss K, Cahan P, McCaffery T, Galante A, Soteropoulos P, Pumfery A, Fujii M, Kashanchi F: Involvement of HTLV-I Tax and CREB in aneuploidy: a bioinformatics approach. Retrovirology; 2006 Jul 05;3:43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adult T-cell leukemia (ATL) is a complex and multifaceted disease associated with human T-cell leukemia virus type 1 (HTLV-I) infection.
  • Tax, the viral oncoprotein, is considered a major contributor to cell cycle deregulation in HTLV-I transformed cells by either directly disrupting cellular factors (protein-protein interactions) or altering their transcription profile.
  • Therefore by examining which factors upregulate a particular set of promoters we may begin to understand how Tax orchestrates leukemia development.
  • RESULTS: We observed that CTLL cells stably expressing wild-type Tax (CTLL/WT) exhibited aneuploidy as compared to a Tax clone deficient for CREB transactivation (CTLL/703).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2003 Jun 23;161(6):1067-79 [12810701.001]
  • [Cites] J Biol Chem. 1988 Jul 15;263(20):9879-86 [2454922.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3467-75 [2850495.001]
  • [Cites] Int J Cancer. 1989 Feb 15;43(2):250-3 [2917802.001]
  • [Cites] Science. 1990 Jan 26;247(4941):464-7 [2405488.001]
  • [Cites] Genome. 1989;31(2):662-7 [2698836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(22):8711-5 [2247439.001]
  • [Cites] Anal Biochem. 1990 Nov 1;190(2):266-70 [1705398.001]
  • [Cites] Oncogene. 1991 Jun;6(6):1023-9 [1906155.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1851-7 [1833716.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Mol Cell Biol. 1992 Jun;12(6):2826-36 [1534143.001]
  • [Cites] Nature. 1992 Aug 6;358(6386):512-4 [1641041.001]
  • [Cites] Virology. 1993 Mar;193(1):456-9 [8438579.001]
  • [Cites] J Cell Sci. 1994 Jan;107 ( Pt 1):9-16 [8175926.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5269-81 [12861013.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5141-9 [12910251.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37736-44 [12842897.001]
  • [Cites] J Cell Biol. 2003 Oct 13;163(1):21-6 [14557244.001]
  • [Cites] J Cell Biol. 2003 Oct 27;163(2):215-22 [14581449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13314-9 [14585930.001]
  • [Cites] Cell. 2003 Oct 31;115(3):355-67 [14636562.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):339-42 [8090203.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):342-5 [8090204.001]
  • [Cites] Semin Cancer Biol. 1994 Aug;5(4):285-94 [7803765.001]
  • [Cites] J Cell Biol. 1996 Feb;132(4):617-33 [8647893.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S179-85 [8797721.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1995;60:803-11 [8824455.001]
  • [Cites] Cell. 1996 Nov 1;87(3):447-58 [8898198.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6101-4 [9045619.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9141-6 [9256449.001]
  • [Cites] Eur J Cell Biol. 1997 Sep;74(1):10-9 [9309386.001]
  • [Cites] Adv Second Messenger Phosphoprotein Res. 1997;31:191-204 [9344252.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3620-32 [9584203.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4370-8 [9687505.001]
  • [Cites] J Cell Biol. 1998 Aug 10;142(3):763-74 [9700164.001]
  • [Cites] Trends Cell Biol. 1998 Aug;8(8):310-8 [9704407.001]
  • [Cites] Cell Growth Differ. 1998 Aug;9(8):651-65 [9716182.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;41(2):154-67 [9786090.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12906-11 [9789013.001]
  • [Cites] Science. 2000 May 5;288(5467):867-70 [10797011.001]
  • [Cites] J Virol. 2000 Aug;74(16):7270-83 [10906181.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6996-7006 [10958694.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1695-700 [11080812.001]
  • [Cites] Virology. 2001 Jan 5;279(1):38-46 [11145887.001]
  • [Cites] Cell. 2001 May 18;105(4):445-57 [11371342.001]
  • [Cites] J Cell Biol. 2001 Jul 23;154(2):267-73 [11470816.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31851-7 [11435441.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(20):7065-77 [11564889.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):626-34 [11756557.001]
  • [Cites] Nat Cell Biol. 2001 Dec;3(12):1086-91 [11781570.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5187-93 [11729202.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Feb;128(2):114-8 [11862483.001]
  • [Cites] J Cell Biol. 2002 Jun 24;157(7):1125-37 [12070128.001]
  • [Cites] J Biomed Sci. 2002 Jul-Aug;9(4):292-8 [12145525.001]
  • [Cites] J Cell Sci. 2002 Sep 15;115(Pt 18):3547-55 [12186941.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7066-82 [12242286.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Virology. 2003 Jan 20;305(2):229-39 [12573569.001]
  • [Cites] Mol Biol Cell. 2003 Feb;14(2):685-97 [12589063.001]
  • [Cites] J Virol. 2003 Apr;77(8):4731-8 [12663780.001]
  • [Cites] Mol Cell Biochem. 2003 Mar;245(1-2):99-113 [12708749.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] J Gen Virol. 2003 Dec;84(Pt 12):3203-14 [14645902.001]
  • [Cites] Genes Dev. 2003 Dec 1;17(23):2902-21 [14633972.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):495-508 [14530271.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):1-39 [14715909.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):434-9 [14733924.001]
  • [Cites] Genes Immun. 2004 Jan;5(1):16-25 [14735145.001]
  • [Cites] Curr Biol. 2004 Jan 20;14(2):R70-2 [14738753.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):165-72 [14761919.001]
  • [Cites] DNA Seq. 2003 Dec;14(6):436-41 [15018354.001]
  • [Cites] BMC Bioinformatics. 2004 Feb 25;5:18 [15053845.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):336-61 [15129647.001]
  • [Cites] EMBO Rep. 2004 Jun;5(6):626-31 [15133482.001]
  • [Cites] J Cell Sci. 2004 Jun 15;117(Pt 14):3011-20 [15173315.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3557-61 [9808547.001]
  • [Cites] J Virol. 1999 Feb;73(2):1271-7 [9882331.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):11-9 [9887095.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):1-13 [9973953.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1999;9(1):19-32 [10200909.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):758-63 [10354142.001]
  • [Cites] Oncogene. 1999 Jul 22;18(29):4254-61 [10435638.001]
  • [Cites] Mol Cell. 1999 Jul;4(1):21-33 [10445024.001]
  • [Cites] Mol Microbiol. 1999 Sep;33(5):904-18 [10476026.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49542-50 [15355977.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54590-8 [15485811.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):563-74 [15632059.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):63-8 [15623561.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):195-201 [15665856.001]
  • [Cites] Hum Mol Genet. 2005 Mar 15;14(6):813-25 [15703196.001]
  • [Cites] Cell Res. 2005 Mar;15(3):143-9 [15780175.001]
  • [Cites] J Cell Biol. 2005 Apr 11;169(1):49-60 [15824131.001]
  • [Cites] Mol Cell Biol. 2005 May;25(9):3553-62 [15831461.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4683-9 [15930286.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] J Virol. 1999 Dec;73(12):9917-27 [10559304.001]
  • [Cites] Methods. 1999 Nov;19(3):425-33 [10579938.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):26-33 [10594005.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):405-16 [10662768.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1257-65 [10713667.001]
  • [Cites] Genetics. 2000 Apr;154(4):1509-21 [10747049.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3554-9 [12824364.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3511-6 [12839935.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2793-808 [12857865.001]
  • [Cites] Retrovirology. 2005;2:45 [16014171.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7071-80 [16103054.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5938-51 [16155601.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Plant Physiol. 2005 Sep;139(1):316-28 [16126853.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):773-85 [16195750.001]
  • [Cites] Stem Cells. 2005 Nov-Dec;23(10):1634-42 [16099994.001]
  • [Cites] Genome Res. 2005 Dec;15(12):1729-40 [16339371.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):438-47 [16158050.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W191-4 [15215378.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):4966-74 [15107832.001]
  • [Cites] Mol Biol Cell. 2004 Jul;15(7):3366-78 [15090617.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):422-4 [15004522.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(20):8938-50 [15456868.001]
  • [Cites] J Virol. 2004 Nov;78(21):11686-95 [15479810.001]
  • [Cites] Cell Immunol. 1983 Jul 1;79(1):68-80 [6574822.001]
  • [Cites] Jpn J Clin Oncol. 1983;13 Suppl 2:209-14 [6603529.001]
  • [Cites] Blood. 1985 Jul;66(1):120-7 [2988665.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Aug;83(15):5512-6 [3526331.001]
  • (PMID = 16822311.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI44357; United States / NIAID NIH HHS / AI / R01 AI043894; United States / PHS HHS / / 13969; United States / NIAID NIH HHS / AI / AI43894; United States / NIAID NIH HHS / AI / R29 AI044357
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Gene Products, tax; EC 2.7.7.- / DNA Polymerase II
  • [Other-IDs] NLM/ PMC1553470
  •  go-up   go-down


11. Ingram PR, Howman R, Leahy MF, Dyer JR: Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis; 2007 Jun 15;44(12):e115-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Antineoplastic Agents / adverse effects. Cryptococcus neoformans / immunology. Immune System Diseases / immunology. Leukemia, Prolymphocytic / immunology. Leukemia, T-Cell / immunology

  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17516390.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


12. Su XY, Xu X, Tang Y, Li GD: [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Aug;38(8):542-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of hematolymphoid malignancy by using effusion fluid cytology specimens: a study of 33 cases].
  • METHODS: The cytospin preparations/smears and cell block sections of effusion cytology specimens from 33 cases of hematolymphoid malignancy were retrospectively reviewed.
  • In selected cases, in-situ hybridization for Epstein-Barr virus-encoded RNA and immunoglobulin and T-cell receptor gene rearrangement study were carried out as indicated.
  • RESULTS: There were 33 cases of hematolymphoid malignancy, including 12 cases of T-lymphoblastic leukemia/lymphoma, 16 cases of mature B cell neoplasm (including 9 cases of diffuse large B-cell lymphoma, 2 cases of Burkitt lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma and 1 case of mantle cell lymphoma), 3 cases of mature T or NK-cell neoplasm (including 1 case of extranodal nasal NK/T-cell lymphoma, 1 case of angioimmunoblastic T-cell lymphoma and 1 case of T-cell prolymphocytic leukemia), 1 case of myeloid sarcoma and 1 case of mast cell sarcoma.
  • Amongst the 33 cases studied, 16 represented disease relapses, including 8 cases of diffuse large B-cell lymphoma, 2 cases of plasmacytoma/multiple myeloma, 2 cases of B-small lymphocytic leukemia/lymphoma, 1 case of T-lymphoblastic leukemia/lymphoma, 1 case of angioimmunoblastic T-cell lymphoma, 1 case of mantle cell lymphoma and 1 case of mast cell sarcoma.
  • The remaining 17 cases showed serous effusion as the primary manifestation, with the diagnosis primarily made upon cytologic examination.
  • The cytologic findings seen in all the 33 cases studied were in agreement with the corresponding histologic diagnosis.
  • CONCLUSIONS: Diagnosis of hematolymphoid malignancy by effusion fluid cytology specimens is possible, especially when coupled with the clinical history, immunophenotype, in-situ hybridization and gene rearrangement study findings.
  • This is especially so for cases with disease relapses.
  • [MeSH-major] Ascitic Fluid / pathology. Cytodiagnosis / methods. Lymphoma, Large B-Cell, Diffuse / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Child. Female. Humans. Immunohistochemistry. Lymphoma, Extranodal NK-T-Cell / diagnosis. Lymphoma, Extranodal NK-T-Cell / metabolism. Lymphoma, Extranodal NK-T-Cell / pathology. Male. Middle Aged. Multiple Myeloma / diagnosis. Multiple Myeloma / metabolism. Multiple Myeloma / pathology. Plasmacytoma / diagnosis. Plasmacytoma / metabolism. Plasmacytoma / pathology. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021966.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Nguyen-Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff-Tavernier M, Ong J, Berger R, Leblond V, Merle-Béral H: Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. Cancer Genet Cytogenet; 2005 May;159(1):74-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin.
  • Burkitt-type acute leukemia cells were present in the bone marrow of a patient with B-prolymphocytic leukemia diagnosed from peripheral blood cell morphology.
  • These data indicated the common origin of the two coexisting leukemias and are the first example of such occurrence in a leukemic patient.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Prolymphocytic / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic
  • [MeSH-minor] Bone Marrow / pathology. Cell Lineage. Cytogenetic Analysis. Female. Gene Rearrangement. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860362.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Marie I, Robaday S, Kerleau JM, Jardin F, Levesque H: Typhlitis as a complication of alemtuzumab therapy. Haematologica; 2007 May;92(5):e62-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is an effective immunotherapeutic agent in patients with malignancies such as non-Hodgkin lymphoma, B cell chronic lymphocytic leukemia and T cell pro- lymphocytic leukemia.
  • We recently observed a case of particular interest as the patient with T cell prolymphocytic leukaemia treated with alemtuzumab, exhibited symptomatic reactivation of CMV infection and developed subsequently typhlitis.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Antineoplastic Agents / adverse effects. Typhlitis / diagnosis. Typhlitis / etiology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Female. Humans. Leukemia, Prolymphocytic / immunology. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / immunology. Leukemia, T-Cell / therapy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562596.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


15. Robak T: Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity. Curr Med Chem; 2009;16(18):2212-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel drugs for chronic lymphoid leukemias: mechanism of action and therapeutic activity.
  • Chronic lymphoid leukemias include well defined mature B-cell and T-cell neoplasms with diverse natural history and specific morphological, immunophenotypic and molecular characteristics.
  • The most common adult leukemia in the Western world is chronic lymphocytic leukemia (CLL).
  • Rarer indolent lymphoid leukemias include prolymphocytic leukemia, hairy cell leukemia, large granular lymphocyte leukemia and T-cell leukemia/lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Design. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519388.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 230
  •  go-up   go-down


16. Madaris L: T-cell prolymphocytic leukemia: A rare disease in an elderly female. J Am Acad Nurse Pract; 2010 Dec;22(12):648-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: A rare disease in an elderly female.
  • This report includes a review of the morphology of T-cell prolymphocytic leukemia (PLL), diagnosis, and the treatment options considered.
  • DATA SOURCES: T-cell PLL is a rare blood disorder that represents a very small number of all chronic leukemias.
  • An extensive review of scientific literature related to the cell morphology and pathology of this disease, as well as clinical trials of treatment options provided the background for this case report.
  • CONCLUSION: A diagnosis of T-cell PLL was made after a computed tomography scan of the abdomen confirmed splenomegaly and a bone marrow biopsy showed a hypercellular marrow infiltrated with numerous small lymphocytes, consistent with this disease.
  • Currently, there is no optimal treatment for T-cell PLL, but alemtuzumab has shown success with extending survival 1-3 years.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia, Prolymphocytic, T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 The Author Journal compilation ©2010 American Academy of Nurse Practitioners.
  • (PMID = 21129072.001).
  • [ISSN] 1745-7599
  • [Journal-full-title] Journal of the American Academy of Nurse Practitioners
  • [ISO-abbreviation] J Am Acad Nurse Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


17. Robak T: Emerging drugs for rarer chronic lymphoid leukemias. Expert Opin Emerg Drugs; 2008 Mar;13(1):95-118
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging drugs for rarer chronic lymphoid leukemias.
  • BACKGROUND: Rarer indolent lymphoid leukemias include well defined mature B-cell and T-cell neoplasm with widely varying natural history and specific morphological, immunophenotypic and molecular characteristics.
  • Among these are prolymphocytic leukemia (PLL), hairy cell leukemia (HCL) and its variants, large granular lymphocyte leukemia (LGLL) and adult T-cell leukemia/lymphoma (ATLL).
  • OBJECTIVE: To present current therapies and emerging drugs potentially useful in the treatment of rarer chronic lymphoid leukemias.
  • Future research should focus on the novel therapeutic strategies based on the molecular pathogenic mechanisms and the development of new targeted therapies for each distinct chronic lymphoid leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drugs, Investigational / therapeutic use. Leukemia, Lymphoid / drug therapy
  • [MeSH-minor] Animals. Chronic Disease. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321151.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drugs, Investigational
  • [Number-of-references] 189
  •  go-up   go-down


18. Troeger A, Glouchkova L, Escherich G, Siepermann M, Hanenberg H, Janka-Schaub G, Göbel U, Ackermann B, Dilloo D: Reduced expression and defective modulation of TNF receptor/ligand family molecules on proB-ALL blasts. Klin Padiatr; 2008 Nov-Dec;220(6):353-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is a subgroup of pediatric patients with an immature immunophenotype of proB-ALL that still poses a therapeutic challenge, even if the overall prognosis in B cell precursor acute lymphoblasic leukemia (BCP-ALL) is very good.
  • [MeSH-major] Antigens, CD40 / genetics. Blast Crisis / immunology. Gene Expression Regulation, Leukemic / genetics. Gene Expression Regulation, Leukemic / immunology. Immunophenotyping. Leukemia, Prolymphocytic, B-Cell / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Receptors, Tumor Necrosis Factor / immunology
  • [MeSH-minor] Adolescent. Antigens, CD80. Antigens, CD86 / genetics. Antigens, CD86 / immunology. Child. Child, Preschool. Fas Ligand Protein / immunology. Female. Humans. Infant. Male. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Prognosis. Up-Regulation / immunology

  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949670.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Antigens, CD80; 0 / Antigens, CD86; 0 / Fas Ligand Protein; 0 / Receptors, Tumor Necrosis Factor
  •  go-up   go-down


19. Dimeski G, Bird R: Hyperleukocytosis: pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis. Clin Chem Lab Med; 2009;47(7):880-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleukocytosis: pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis.

  • MedlinePlus Health Information. consumer health - Potassium.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575549.001).
  • [ISSN] 1437-4331
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gases; RWP5GA015D / Potassium
  •  go-up   go-down


20. Valiev TT, Vinogradova IuE, Chernova NG, Mar'in DS, Volkova IaK, Petrova VI, Bulanov AIu, Kalinin NN, Semenova EA, Gretsov EM, Kravchenko SK, Kremenetskaia AM, Vorob'ev AI: [Remission in T-cell prolymphocytic leukemia during the FMC treatment course]. Ter Arkh; 2006;78(7):87-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Remission in T-cell prolymphocytic leukemia during the FMC treatment course].
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy

  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944758.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


21. Li ZQ, Chen HS, Liu EB, Sun Q, Fang LH, Sun FJ, Zhang PH, Yang QY, Qiu LG: [Clinicopathologic study of 15 splenectomy specimens of patients with hairy cell leukemia]. Zhonghua Bing Li Xue Za Zhi; 2009 Nov;38(11):769-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 15 splenectomy specimens of patients with hairy cell leukemia].
  • OBJECTIVE: To investigate the clinicopathologic features, diagnosis, differential diagnosis and the prognosis of hairy cell leukemia (HCL).
  • The abundant cytoplasm and prominent cell border resulted in a "fried egg" appearance.
  • Definite diagnosis of HCL requires a combined histological and immunohistochemical assessment of the splenectomy specimen, bone marrow biopsy and aspirate.
  • [MeSH-major] Leukemia, Hairy Cell / metabolism. Leukemia, Hairy Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Spleen / pathology. Splenectomy
  • [MeSH-minor] Adult. Aged. Annexin A1 / metabolism. Antigens, CD11c / metabolism. Antigens, CD20 / metabolism. Antigens, CD45 / metabolism. Antigens, CD79 / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Prolymphocytic / metabolism. Leukemia, Prolymphocytic / pathology. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Lymphoma, Mantle-Cell / metabolism. Lymphoma, Mantle-Cell / pathology. Male. Middle Aged. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079018.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Annexin A1; 0 / Antigens, CD11c; 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / Ki-67 Antigen; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


22. Thorat KB, Gujral S, Kumar A, Nair CN: Small cell variant of T-cell prolymphocytic leukemia exhibiting suppressor phenotype. Leuk Lymphoma; 2006 Aug;47(8):1711-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell variant of T-cell prolymphocytic leukemia exhibiting suppressor phenotype.
  • [MeSH-major] Leukemia, Prolymphocytic / pathology. Leukemia, T-Cell / pathology. T-Lymphocytes, Regulatory / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966296.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


23. Chen J, Petrus M, Bryant BR, Nguyen VP, Goldman CK, Bamford R, Morris JC, Janik JE, Waldmann TA: Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood; 2010 Dec 23;116(26):5948-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia.
  • Adult T-cell leukemia (ATL), a heterogeneous disease, can be divided into smoldering, chronic, lymphoma, and acute types clinically.
  • Here, we demonstrated that smoldering/chronic ATL peripheral blood mononuclear cells spontaneously proliferated ex vivo in a cytokine (interleukin-12 [IL-12]/IL-9/IL-15)-dependent manner, while acute-type ATL peripheral blood mononuclear cells did not proliferate or proliferated independent of cytokines.
  • In conclusion, our data provide evidence that there is autocrine/paracrine cytokine stimulation of leukemic cell proliferation in patients with smoldering/chronic ATL that could be targeted for treatment.

  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1043-8 [10706122.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4624-33 [15735688.001]
  • [Cites] Immunity. 2002 Nov;17(5):537-47 [12433361.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6390-4 [12438221.001]
  • [Cites] J Immunol Methods. 2003 Jul;278(1-2):221-34 [12957410.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] Blood. 1981 Sep;58(3):645-7 [6455129.001]
  • [Cites] Science. 1984 Mar 9;223(4640):1086-7 [6320374.001]
  • [Cites] J Immunol. 1987 May 1;138(9):3069-74 [2883237.001]
  • [Cites] Blood. 1987 Nov;70(5):1407-11 [2889484.001]
  • [Cites] Neurology. 1988 Aug;38(8):1302-7 [2899862.001]
  • [Cites] Leukemia. 1988 Nov;2(11):728-33 [2972890.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5218-22 [2367534.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Immunol. 1992 May 15;148(10):3256-63 [1374452.001]
  • [Cites] Am J Hematol. 1992 Dec;41(4):258-63 [1288288.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):741-50 [8094736.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Leukemia. 1994 Apr;8(4):652-8 [8152260.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 May;1(3):273-82 [7496962.001]
  • [Cites] Leuk Lymphoma. 1997 Aug;26(5-6):479-87 [9389355.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2452-7 [9482906.001]
  • [Cites] Microbiol Mol Biol Rev. 1999 Jun;63(2):308-33 [10357853.001]
  • [Cites] Trends Mol Med. 2004 Nov;10(11):532-41 [15519279.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1553-9 [16236609.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1648-53 [16646068.001]
  • [Cites] Oncogene. 2007 Feb 22;26(8):1245-55 [16909099.001]
  • [Cites] Nat Med. 2007 May;13(5):527-8 [17479090.001]
  • [Cites] Int J Oncol. 2007 Jun;30(6):1343-8 [17487354.001]
  • [Cites] Int Arch Allergy Immunol. 2007;143 Suppl 1:71-5 [17541281.001]
  • [Cites] Blood. 2008 May 15;111(10):5163-72 [18339896.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2400-10 [18509087.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4016-26 [19131553.001]
  • [Cites] Am J Pathol. 2010 Jan;176(1):402-15 [20019193.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2602-9 [11160322.001]
  • (PMID = 20858854.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cytokines
  • [Other-IDs] NLM/ PMC3031384
  •  go-up   go-down


24. Dearden CE: T-cell prolymphocytic leukemia. Med Oncol; 2006;23(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia.
  • T-cell prolymphocytic leukemia (T-PLL) is a rare aggressive post-thymic malignancy with poor response to conventional treatment and short survival.
  • It can readily be distinguished from other T-cell leukemias on the basis of the distinctive morphology, immunophenotype, and cytogenetics.
  • Consistent chromosomal translocations involving the T-cell receptor gene and one of two protooncogenes (TCL-1 and MTCP-1) are seen in the majority of cases and are likely to be involved in the pathogenesis of the disorder.
  • However, relapse is inevitable and strategies using both autologous and allogeneic stem cell transplantation are currently being explored.
  • [MeSH-major] Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1996 Oct 1;10(19):2411-22 [8843194.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2331-4 [12613520.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Ann Hematol. 2001 Dec;80(12):749-51 [11797117.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):724-32 [9074412.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1155-9 [9334731.001]
  • [Cites] Science. 1985 Mar 1;227(4690):1044-7 [3919442.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1923-7 [8634440.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1305-11 [9264385.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):248-54 [11391795.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5452-6 [9407948.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):336-41 [11241786.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2475-83 [8361760.001]
  • [Cites] Blood. 1998 May 15;91(10):3920-6 [9573030.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):921-7 [8703826.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] Lancet. 1973 Aug 4;2(7823):232-4 [4124423.001]
  • (PMID = 16645226.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


25. Chaar BT, Petruska PJ: Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol; 2007 May;82(5):417
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Prolymphocytic / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. B-Lymphocytes / pathology. Combined Modality Therapy. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Remission Induction. Transplantation, Autologous

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160995.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


26. Morales M, Trujillo M, del Carmen Maeso M, Piris MA: Thymoma and progressive T-cell lymphocytosis. Ann Oncol; 2007 Mar;18(3):603-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymoma and progressive T-cell lymphocytosis.

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074971.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


27. Gandhi V, Tam C, O'Brien S, Jewell RC, Rodriguez CO Jr, Lerner S, Plunkett W, Keating MJ: Phase I trial of nelarabine in indolent leukemias. J Clin Oncol; 2008 Mar 1;26(7):1098-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of nelarabine in indolent leukemias.
  • PURPOSE: To test whether nelarabine is an effective agent for indolent leukemias and to evaluate whether there is a relationship between cellular pharmacokinetics of the analog triphosphate and clinical responses.
  • PATIENTS AND METHODS: Thirty-five patients with relapsed/refractory leukemias (n = 24, B-cell chronic lymphocytic leukemia and n = 11, T-cell prolymphocytic leukemia) were entered onto three different protocols.
  • Pharmacokinetics of plasma nelarabine and arabinosylguanine (ara-G) and of cellular ara-G triphosphate (ara-GTP) were similar in the two groups of diagnoses, and the elimination of ara-GTP from leukemia cells was slow (median, > 24 hours).
  • CONCLUSION: Nelarabine is an effective regimen against indolent leukemias, and combining it with fludarabine was most promising.
  • Determination of tumor cell ara-GTP levels may provide a predictive test for response to nelarabine.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Prolymphocytic, T-Cell / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18309944.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57629; United States / NCI NIH HHS / CA / CA81534
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Arabinonucleotides; 60158CV180 / nelarabine; 72490-81-4 / 9-beta-D-arabinofuranosylguanosine 5'-triphosphate; 86-01-1 / Guanosine Triphosphate; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


28. Kar R, Kumar R, Tyagi S: De-novo CD5 + B- prolymphocytic leukemia (PLL) presenting at younger age with favourable outcome. Turk J Haematol; 2008 Sep 5;25(3):149-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De-novo CD5 + B- prolymphocytic leukemia (PLL) presenting at younger age with favourable outcome.
  • [Transliterated title] Küçük yaşta olumlu prognoz ile seyreden de-novo CD5 + B- prolenfositik lösemi (PLL).
  • B-cell prolymphocytic leukemia (B-PLL) comprises 1% of chronic lymphocytic leukemias.
  • They have longer median survival compared with de novo B-PLL which are commonly CD5 negative and are more aggressive with an older age of presentation.
  • Herewith, we describe a 48-year-old male of de-novo CD5+ B-PLL presenting with minimal lymphadenopathy and massive splenomegaly with 90% atypical lymphoid cells in the peripheral smear and bone marrow.
  • Our case illustrates a de-novo B-PLL with aberrant CD5 positivity who had a short duration of illness, younger age at presentation and favourable treatment outcome.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264708.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


29. Gribben JG, Hallek M: Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol; 2009 Mar;144(6):818-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The humanized anti-CD52 monoclonal antibody alemtuzumab belongs to the family of Campath-1 antibodies, which were initially developed for their ability to prevent graft-versus-host disease (GVHD) and graft rejection in stem cell transplantation.
  • Alemtuzumab is indicated for the treatment of chronic lymphocytic leukaemia (CLL) and has demonstrated considerable activity in relapsed/refractory disease and in previously untreated disease.
  • It has been shown to induce minimal residual disease-negative responses as a single agent or as part of consolidation therapy in a meaningful proportion of patients with CLL and has shown promising activity in patients with high-risk cytogenetic markers.
  • Alemtuzumab may also have significant activity in T-cell malignancies, such as mycosis fungoides and T-cell prolymphocytic leukaemia.
  • Recent studies also have evaluated alemtuzumab as part of a conditioning regimen to prevent GVHD in stem cell transplantation.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Glycoproteins / immunology. Graft vs Host Disease / prevention & control. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Stem Cell Transplantation. Transplantation Conditioning

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183194.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Number-of-references] 80
  •  go-up   go-down


30. Bain BJ, Fawcett N: A T-lineage neoplasm-Which one? Am J Hematol; 2009 Oct;84(10):678
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, CD / biosynthesis. Antigens, Neoplasm / analysis. Antigens, Neoplasm / biosynthesis. Diagnosis, Differential. Humans. Immunophenotyping. Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia, Prolymphocytic, T-Cell / immunology. Leukemia, Prolymphocytic, T-Cell / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373891.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


31. Weiss A: FeLV-associated chronic lymphocytic leukemia. J Feline Med Surg; 2010 Dec;12(12):995; author reply 996
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FeLV-associated chronic lymphocytic leukemia.
  • [MeSH-major] Cat Diseases / virology. Leukemia, Feline / virology. Leukemia, Lymphocytic, Chronic, B-Cell / veterinary. Leukemia, Prolymphocytic, T-Cell / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Feline Med Surg. 2010 Apr;12(4):341-4 [19945894.001]
  • (PMID = 21126679.001).
  • [ISSN] 1532-2750
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


32. Singhal M, Raina V, Gupta R, Das P: T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report. Cases J; 2010;3:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report.
  • It includes acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); however T-cell prolymphocytic leukemia (T-PLL) has not been described earlier in relation to breast cancer and its therapy.
  • T-PLL is a rare chronic T-cell lymphoproliferative disease with a mature post-thymic T-cell immunophenotype and aggressive clinical course.
  • She was doing well on follow up until the completion of fifth year of her disease, when she presented with complaints of mild fever and weakness.
  • Peripheral blood examination revealed medium sized lymphoid cells, constituting almost 75% of total nucleated cell population.
  • Immunophenotying, established a diagnosis of post thymic T-cell prolymphocytic leukemia.
  • Unfortunately, both her malignancies progressed after an initial stable disease of two months.
  • CONCLUSION: Our case describes the potential of breast chemotherapy to cause grave second hematological malignancies of the T-cell lymphoid lineage, not described earlier.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):791-8 [19124806.001]
  • [Cites] BMC Cancer. 2007;7:152 [17683622.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):292-300 [17159192.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4179-91 [15961765.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1745-51 [1594016.001]
  • [Cites] J Clin Oncol. 1985 Dec;3(12):1640-58 [3906049.001]
  • [Cites] Clin Breast Cancer. 2003 Oct;4(4):273-9 [14651772.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2722-30 [8874333.001]
  • (PMID = 20076807.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806858
  •  go-up   go-down


33. Crisostomo RH, Fernandez JA, Caceres W: Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia. Leuk Res; 2007 May;31(5):699-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia.
  • We report a case of a 64-year-old white female patient, who presented with symptomatic anemia (Hgb: 6.8g/dl), thrombocytopenia (platelets: 94,000/mcl) and leukocytosis (WBC: 156,000/mcl).
  • Peripheral blood smear revealed markedly increased white blood cell count with predominance of atypical lymphoid cells of intermediate size, moderately dense chromatin, and prominent large single nucleoli.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Leukemia, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997373.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


34. Dearden CE: T-cell prolymphocytic leukemia. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S239-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia.
  • T-cell prolymphocytic leukemia is a rare postthymic malignancy with distinctive clinical, morphologic, immunophenotypic, and cytogenetic features.
  • Nevertheless, responses are relatively short, and the only potential curative treatment is allogeneic stem cell transplantation.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / diagnosis. Leukemia, Prolymphocytic, T-Cell / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Gene Expression Regulation, Leukemic. Humans. Immunophenotyping. Male. Medical Oncology / methods. Middle Aged. Pentostatin / therapeutic use. Stem Cell Transplantation / methods. Transplantation, Homologous / methods. Treatment Outcome

  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778847.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab
  • [Number-of-references] 38
  •  go-up   go-down


35. Hofbauer SW, Piñón JD, Brachtl G, Haginger L, Wang W, Jöhrer K, Tinhofer I, Hartmann TN, Greil R: Modifying akt signaling in B-cell chronic lymphocytic leukemia cells. Cancer Res; 2010 Sep 15;70(18):7336-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modifying akt signaling in B-cell chronic lymphocytic leukemia cells.
  • Emerging evidence suggests that the survival of B-cell chronic lymphocytic leukemia (CLL) cells is dependent on microenvironmental influences such as antigenic stimulation and support by stromal cells.
  • We investigated the role of Akt and its modulation by the protooncogene T-cell leukemia 1a (Tcl1a) in the survival pathways of primary CLL samples and CLL-derived prolymphocytic cell lines MEC-1 and MEC-2.
  • Akt activation was increased by the protective presence of human bone marrow stromal cells and B-cell receptor mimicking signals but antagonized by direct Akt blockade with the novel specific inhibitor AiX, with preferential apoptosis induction in CLL cells with an unmutated immunoglobulin status, which predicts poor clinical outcome.
  • In contrast, decreasing Tcl1a levels by small interfering RNA reduced Akt activation in the fludarabine-insensitive CLL cell line MEC-2 and sensitized the malignant cells to fludarabine treatment.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Enzyme Inhibitors / pharmacology. Humans. Oxazines / pharmacology. RNA, Small Interfering / genetics. Signal Transduction. Transfection


36. Kurihara K, Harashima N, Hanabuchi S, Masuda M, Utsunomiya A, Tanosaki R, Tomonaga M, Ohashi T, Hasegawa A, Masuda T, Okamura J, Tanaka Y, Kannagi M: Potential immunogenicity of adult T cell leukemia cells in vivo. Int J Cancer; 2005 Mar 20;114(2):257-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential immunogenicity of adult T cell leukemia cells in vivo.
  • Experimental vaccines targeting human T cell leukemia virus type-I (HTLV-I) Tax have been demonstrated in a rat model of HTLV-I-induced lymphomas.
  • However, the scarcity of HTLV-I-expression and the presence of defective HTLV-I-proviruses in adult T cell leukemia (ATL) cells have raised controversy about the therapeutic potential of HTLV-I-targeted immunotherapy in humans.
  • In flow cytometric analysis, we found that 3 of 5 acute-type and six of fifteen chronic-type ATL patients tested showed significant induction of HTLV-I Tax and Gag in their ATL cells in a 1-day culture.
  • Representative CTL epitopes restricted by HLA-A2 or A24 were conserved in 4 of 5 acute-type ATL patients tested.
  • Furthermore, spleen T cells from rats, which had been subcutaneously inoculated with formalin-fixed uncultured ATL cells, exhibited a strong interferon gamma-producing helper T cell responses specific for HTLV-I Tax-expressing cells.
  • Our study indicated that ATL cells from about half the patients tested readily express HTLV-I antigens including Tax in vitro, and that ATL cells express sufficient amounts of Tax or Tax-induced antigens to evoke specific T cell responses in vivo.
  • [MeSH-minor] Adult. Aged. Animals. Base Sequence. DNA Primers. Female. Humans. Japan. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia, Prolymphocytic, T-Cell / virology. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / virology. Male. Middle Aged. Polymerase Chain Reaction. Rats. Rats, Inbred F344. Reference Values. Transplantation, Heterologous / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15551352.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


37. Zhang JF, Miao KR, Qiu HR, Yang H, Wu YJ, Qiao C, Li JY: [Acute myeloid leukemia with the morphological characteristics of prolymphocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct;16(5):1211-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myeloid leukemia with the morphological characteristics of prolymphocytic leukemia].
  • To investigate the clinical, cellular morphology, immunophenotype, and cytogenetic characteristics of acute myeloid leukemia (AML) which are very similar to the morphological characteristics of prolymphocytic leukemia (PLL), the morphological features of bone marrow cells from patient were observed by light microscope, the immunophenotypes were detected by flow cytometry, the karyotypes were analyzed by conventional cytogenetic method, the hybridization signals were determined by fluorescence in situ hybridization.
  • The results indicated that the clinical features were in accordance with acute leukemia and the immunophenotyping results showed malignant cells originated from myeloid lineage, while the cytomorphology analysis showed that the blastic cells were more like the lymphoid lineage.
  • In conclusion, acute leukemia has high heterogenicity, which could be defined as AML, but more like lymphocytic origination by morphological study.
  • Immunophenotyping analysis could contribute to the final diagnosis of malignant cells.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928630.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Le Toriellec E, Despouy G, Pierron G, Gaye N, Joiner M, Bellanger D, Vincent-Salomon A, Stern MH: Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. Blood; 2008 Feb 15;111(4):2321-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia.
  • T-cell prolymphocytic leukemia (T-PLL) is consistently associated with inactivation of the ATM gene and chromosomal re-arrangements leading to an overexpression of MTCP1/TCL1 oncoproteins.
  • The absence of biallelic inactivation of CDKN1B for most patients suggested a haploinsufficiency mechanism for tumor suppression, which was investigated in an animal model of the disease.
  • [MeSH-major] Chromosomes, Human, Pair 12. Intracellular Signaling Peptides and Proteins / deficiency. Intracellular Signaling Peptides and Proteins / genetics. Leukemia, Prolymphocytic, T-Cell / genetics. Sequence Deletion
  • [MeSH-minor] Animals. Ataxia Telangiectasia Mutated Proteins. Cell Cycle Proteins / genetics. Chromosome Mapping. Cyclin-Dependent Kinase Inhibitor p27. DNA Primers. DNA-Binding Proteins / genetics. Gene Deletion. Humans. Mice. Mice, Transgenic. Open Reading Frames. Polymerase Chain Reaction. Polymorphism, Single Nucleotide. Protein-Serine-Threonine Kinases / genetics. Tumor Cells, Cultured. Tumor Suppressor Proteins / genetics

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18073348.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


39. Nusz KJ, Pang NK, Woog JJ: Periorbital edema as the initial presentation of T-cell prolymphocytic leukemia. Ophthal Plast Reconstr Surg; 2006 May-Jun;22(3):215-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periorbital edema as the initial presentation of T-cell prolymphocytic leukemia.
  • Laboratory tests revealed T-cell prolymphocytic leukemia.
  • This life-threatening disorder should be added to the differential diagnosis of eyelid edema.
  • [MeSH-major] Edema / etiology. Eyelid Diseases / etiology. Leukemia, Prolymphocytic / complications. Leukemia, T-Cell / complications. Orbital Diseases / etiology

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16714934.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


40. Dungarwalla M, Matutes E, Dearden CE: Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol; 2008 Jun;80(6):469-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper.
  • Prolymphocytic leukaemias of B and T cell subtype are rare diseases.
  • Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor.
  • Purine analogues and monoclonal antibodies have shown efficacy in B-cell prolymphocytic leukaemia although further studies are warranted.
  • Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T-cell prolymphocytic leukaemia (T-PLL) but responses are still transient and further disease progression is inevitable.
  • While allogeneic stem cell transplant is an attractive option, due to the older age group of T-PLL patients the morbidity and mortality associated with the procedure is significant.
  • [MeSH-major] B-Lymphocytes / immunology. Leukemia, Lymphoid / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Disease Progression. Humans

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331594.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 49
  •  go-up   go-down


41. Reindl L, Bacher U, Dicker F, Alpermann T, Kern W, Schnittger S, Haferlach T, Haferlach C: Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms. Br J Haematol; 2010 Oct;151(1):25-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms.
  • 14q-deletions have been repeatedly described in mature B-cell neoplasms, but not yet characterized in a larger cohort.
  • Based on chromosome banding analysis, the present study identified 47 del(14q) cases in 3054 mature B-cell neoplasms (1·5%) (chronic lymphocytic leukaemia [CLL]: 1·9%; CLL/prolymphocytic leukaemia [PL]: 9·0%; others: 0·2%).
  • In conclusion, the del(14q) is a rare recurrent alteration in diverse mature B-cell neoplasms, shows variable size but distinct clustering of breakpoints, and is associated with short time to treatment.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 14 / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20649559.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


42. Abrams SL, Steelman LS, Shelton JG, Chappell W, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA: Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle; 2010 May;9(9):1839-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of inhibition of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways and chemotherapeutic drugs on cell cycle progression and drug sensitivity were examined in cytokine-dependent FL5.12 hematopoietic cells.
  • When cytokine-dependent FL5.12 cells were cultured in the presence of IL-3, which stimulated multiple proliferation and anti-apoptotic cascades, MEK, PI3K and mTOR inhibitors transiently suppressed but did not totally inhibit cell cycle progression or induce apoptosis while chemotherapeutic drugs such as doxorubicin and paclitaxel were more effective in inducing cell cycle arrest and apoptosis.
  • Doxorubicin was more effective in inducing cell death than paclitaxel.
  • It is important to develop methods to inhibit the growth of such cytokine-dependent cells as they may resemble the leukemia stem cell and other cancer initiating cells.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2008 Jan;22(1):147-60 [17928881.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):216-21 [18256527.001]
  • [Cites] J Virol. 2008 Apr;82(7):3796-802 [18216097.001]
  • [Cites] Cancer Biol Ther. 2007 Nov;6(11):1684-90 [18344680.001]
  • [Cites] Leukemia. 2008 Apr;22(4):708-22 [18337766.001]
  • [Cites] Leukemia. 2008 Apr;22(4):686-707 [18337767.001]
  • [Cites] Cell Cycle. 2008 Feb 15;7(4):533-41 [18431843.001]
  • [Cites] Cell Cycle. 2008 Apr 15;7(8):965-70 [18414037.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1360-70 [18418062.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1371-8 [18421251.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1106-16 [18385752.001]
  • [Cites] Cell Cycle. 2008 Jun 1;7(11):1604-12 [18520179.001]
  • [Cites] Oncogene. 2008 Jul 3;27(29):4086-95 [18332865.001]
  • [Cites] Cell Cycle. 2009 May 1;8(9):1373-9 [19305144.001]
  • [Cites] Cell Cycle. 2009 May 1;8(9):1352-8 [19305151.001]
  • [Cites] Cell Cycle. 2009 May 1;8(9):1338-43 [19342894.001]
  • [Cites] Cell Cycle. 2009 May 15;8(10):1515-25 [19377304.001]
  • [Cites] Rejuvenation Res. 2008 Aug;11(4):801-8 [18729812.001]
  • [Cites] Cell Cycle. 2009 Jun 1;8(11):1711-9 [19411846.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1883-7 [19448395.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1888-95 [19471117.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1901-4 [19471118.001]
  • [Cites] Cell Cycle. 2009 Jun 15;8(12):1896-900 [19478560.001]
  • [Cites] Cell Cycle. 2009 Jul 1;8(13):2005-13 [19550141.001]
  • [Cites] Cell Cycle. 2009 Aug 15;8(16):2509-17 [19633417.001]
  • [Cites] Cell Cycle. 2009 Sep 1;8(17):2810-8 [19657224.001]
  • [Cites] Cell Cycle. 2009 Sep 15;8(18):2975-83 [19713744.001]
  • [Cites] Cell Cycle. 2009 Sep 15;8(18):2951-63 [19713770.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3208-17 [19738435.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3120-4 [19755852.001]
  • [Cites] Cell Cycle. 2009 Oct 15;8(20):3303-6 [19806030.001]
  • [Cites] Adv Enzyme Regul. 2010;50(1):285-307 [19895837.001]
  • [Cites] Expert Opin Emerg Drugs. 2010 Jun;15(2):203-23 [20151845.001]
  • [Cites] Cell Cycle. 2010 May;9(9):1781-91 [20436278.001]
  • [Cites] Cell Cycle. 2010 Apr 15;9(8):1629-38 [20372086.001]
  • [Cites] Cell Cycle. 2008 Jul 1;7(13):1973-82 [18604177.001]
  • [Cites] Cell Cycle. 2008 Aug;7(15):2427-33 [18677110.001]
  • [Cites] Cell Cycle. 2008 Jun 15;7(12):1745-62 [18594202.001]
  • [Cites] Cell Cycle. 2008 Sep 1;7(17):2615-8 [18719390.001]
  • [Cites] Cell Cycle. 2008 Sep 1;7(17):2661-6 [18728388.001]
  • [Cites] Cell Cycle. 2008 Sep 15;7(18):2877-85 [18769155.001]
  • [Cites] Cell Cycle. 2008 Oct;7(19):2949-55 [18818517.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1899-908 [18650843.001]
  • [Cites] Cell Cycle. 2008 Oct;7(20):3133-6 [18927504.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2080-90 [18685611.001]
  • [Cites] Cell Cycle. 2008 Nov 1;7(21):3355-61 [18948731.001]
  • [Cites] Cell Cycle. 2008 Nov 1;7(21):3362-70 [18948750.001]
  • [Cites] Cell Cycle. 2008 Nov 1;7(21):3344-54 [18971624.001]
  • [Cites] Cell Cycle. 2008 Nov 1;7(21):3448-60 [18971636.001]
  • [Cites] Leukemia. 2009 Jan;23(1):25-42 [18800146.001]
  • [Cites] Cell Cycle. 2008 Dec 15;7(24):3798-804 [19066464.001]
  • [Cites] Cell Cycle. 2008 Dec 15;7(24):3805-9 [19098454.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cell Cycle. 2009 Feb 1;8(3):403-13 [19177005.001]
  • [Cites] Nat Struct Mol Biol. 2009 Mar;16(3):294-303 [19219045.001]
  • [Cites] Cell Cycle. 2009 Apr 1;8(7):1000-2 [19270518.001]
  • [Cites] Cell Cycle. 2009 Apr 1;8(7):1026-9 [19270529.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3520-8 [19351820.001]
  • [Cites] Cell Cycle. 2009 May 1;8(9):1314-8 [19279406.001]
  • [Cites] Cell Growth Differ. 1996 Apr;7(4):487-500 [9052990.001]
  • [Cites] Leukemia. 1997 Oct;11(10):1711-25 [9324293.001]
  • [Cites] Leukemia. 2006 Jun;20(6):911-28 [16642045.001]
  • [Cites] Nature. 2006 May 25;441(7092):475-82 [16598206.001]
  • [Cites] Nature. 2006 May 25;441(7092):518-22 [16633340.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1254-60 [16642049.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]
  • [Cites] Cell. 2000 Feb 18;100(4):387-90 [10693755.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4354-64 [11466616.001]
  • [Cites] Oncogene. 2003 Apr 24;22(16):2478-92 [12717425.001]
  • [Cites] Blood. 2003 Aug 1;102(3):972-80 [12702506.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Nov;82(21):7414-8 [3933007.001]
  • [Cites] Oncogene Res. 1989;4(2):97-109 [2785667.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3139-50 [7579409.001]
  • [Cites] Leukemia. 2007 Mar;21(3):427-38 [17215852.001]
  • [Cites] Leukemia. 2007 May;21(5):886-96 [17361225.001]
  • [Cites] Biochim Biophys Acta. 2007 Aug;1773(8):1263-84 [17126425.001]
  • [Cites] Exp Hematol. 2007 Oct;35(10):1538-49 [17889721.001]
  • [Cites] Cell Cycle. 2007 Sep 15;6(18):2268-75 [17890906.001]
  • [Cites] J Cell Biochem. 2007 Dec 15;102(6):1389-99 [17975792.001]
  • [Cites] Leukemia. 2008 Jan;22(1):198-200 [17625605.001]
  • (PMID = 20436269.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098195; United States / NCI NIH HHS / CA / R01CA098195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Butadienes; 0 / Chromones; 0 / Interleukin-3; 0 / Intracellular Signaling Peptides and Proteins; 0 / Morpholines; 0 / Nitriles; 0 / U 0126; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 80168379AG / Doxorubicin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; P88XT4IS4D / Paclitaxel; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC3781183
  •  go-up   go-down


43. Tempescul A, Feuerbach J, Ianotto JC, Dalbies F, Marion V, Le Bris MJ, De Braekeleer M, Berthou C: A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. Ann Hematol; 2009 Jan;88(1):85-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
  • [MeSH-major] Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols. Leukemia, Prolymphocytic, B-Cell / drug therapy. Mitoxantrone. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654781.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


44. Matutes E, Wotherspoon A, Catovsky D: Differential diagnosis in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol; 2007 Sep;20(3):367-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis in chronic lymphocytic leukaemia.
  • The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features.
  • In cases with atypical features, these investigations should be complemented with cytogenetics and/or histology to confirm the diagnosis and to exclude other B-cell disorders.
  • Cell-marker studies provide a robust foundation to establish the diagnosis as the lymphocytes have a distinct immunophenotypic signature.
  • Although no single antigen is exclusively expressed in CLL cells, when several markers are compounded into a scoring system the results allow firming up of the diagnosis.
  • Fluorescence in-situ hybridization (FISH) analysis also provides prognostic information, chiefly by detecting 17 (p53 locus) and 11q deletion, and may determine the type of therapy.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • [MeSH-minor] Bone Marrow / pathology. Diagnosis, Differential. Flow Cytometry. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Leukemia, Hairy Cell / diagnosis. Leukemia, Prolymphocytic / diagnosis. Lymphocytes / pathology. Prognosis. Spleen / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707827.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


45. Jeong KH, Lew BL, Sim WY: Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis. Acta Derm Venereol; 2009;89(5):509-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis.
  • T-cell prolymphocytic leukaemia (T-PLL) is a rare, aggressive neoplasm of mature T lymphocytes.
  • The small cell variant occurs in approximately 20% of T-PLL patients.
  • The skin findings of leukaemia consist of leukaemia-specific skin lesions, which are infiltrated by leukaemia cells, and non-specific lesions.
  • The former type of lesion signifies leukaemia cutis.
  • Leukaemia cutis presents clinically as tumours, nodules, or patches on the scalp, face and trunk.
  • We suspected a hidden malignancy and diagnosed small cell variant T-PLL through blood and bone marrow examination.
  • Most of the atypical lymphocytes stained positively with CD markers such as CD2, CD3, CD4, CD5, CD7 and CD8, thereby confirming the presence of leukaemia cells.
  • To our knowledge, this is the first case of generalized leukaemia cutis from small cell variant of T-PLL presenting with exfoliative dermatitis over the whole body.
  • [MeSH-major] Dermatitis, Exfoliative / etiology. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemic Infiltration. Skin / pathology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Exfoliative Dermatitis.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734979.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone
  •  go-up   go-down


46. Bonanni L, Adami F, Angelini A, Gurrieri C, Cutolo A, Ponchia A, Corbetti F, Thiene G, Semenzato G: Images in cardiovascular medicine. Right atrial mass in a patient with T-cell chronic lymphocytic leukemia: an unusual mechanism of thrombus formation. Circulation; 2007 Dec 18;116(25):e569-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in cardiovascular medicine. Right atrial mass in a patient with T-cell chronic lymphocytic leukemia: an unusual mechanism of thrombus formation.
  • [MeSH-major] Endocardium / pathology. Heart Neoplasms / pathology. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemic Infiltration / pathology. Thrombosis / pathology


47. Ozpuyan F, Meyer P, Ni H, Al-Masri H, Alkan S: Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL). Leuk Lymphoma; 2007 Nov;48(11):2247-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib induces apoptosis in T-cell prolymphocytic leukemia (T-PLL).
  • [MeSH-major] Apoptosis / drug effects. Boronic Acids / pharmacology. Leukemia, Prolymphocytic, T-Cell / pathology. Pyrazines / pharmacology
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Bortezomib. Cell Survival / drug effects. Cryopreservation. Dactinomycin / analogs & derivatives. Dactinomycin / pharmacology. Drug Evaluation, Preclinical. Flow Cytometry. Humans. Time Factors. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990182.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 1CC1JFE158 / Dactinomycin; 69G8BD63PP / Bortezomib; 7240-37-1 / 7-aminoactinomycin D
  •  go-up   go-down


48. Shimizu D, Taki T, Utsunomiya A, Nakagawa H, Nomura K, Matsumoto Y, Nishida K, Horiike S, Taniwaki M: Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. Int J Hematol; 2007 Apr;85(3):212-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma.
  • We analyzed NOTCH1 gene mutation in 53 adults with mature T-cell leukemia/lymphoma: 21 patients with adult T-cell leukemia (ATL), 25 with T-cell non-Hodgkin's lymphoma (T-NHL), and 7 with T-cell prolymphocytic leukemia.
  • We detected a nonsense mutation, C7249T (resulting in Q2417X, where X is a termination codon) in the PEST domain of NOTCH1 in an ATL patient and detected a 3-bp deletion (positions 7234-7236) that resulted in deletion of a proline codon at codon 2412 in the PEST domain of NOTCH1 in a patient with a T-NHL, peripheral T-cell lymphoma-unspecified (PTCL-u).
  • These findings suggest that nonsense mutation in the PEST domain in the ATL case was associated with NOTCH1 signaling through a pathway different from that for T-cell acute lymphoblastic leukemia (T-ALL).
  • Although NOTCH1 mutation occurs infrequently in mature T-cell leukemia/lymphoma, NOTCH1 may be involved in leukemogenesis associated with various forms of T-cell leukemia/lymphoma rather than only with T-ALL.
  • [MeSH-major] Codon, Nonsense. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Receptor, Notch1 / genetics

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Sep 15;104(6):1696-702 [15187027.001]
  • [Cites] Blood. 2002 May 1;99(9):3398-403 [11964309.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34371-8 [11425854.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7505-15 [11003647.001]
  • [Cites] Virchows Arch. 2005 Apr;446(4):416-20 [15756589.001]
  • [Cites] Int J Hematol. 2005 Nov;82(4):277-84 [16298815.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1091-6 [15205204.001]
  • [Cites] Int J Hematol. 2005 Nov;82(4):295-301 [16298817.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1255-64 [16210342.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1841-3 [16079893.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):702-5 [10468859.001]
  • [Cites] Blood. 2004 Dec 1;104(12 ):3697-704 [15292061.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):680-8 [15991363.001]
  • [Cites] Nature. 2005 Sep 8;437(7056):270-4 [16025100.001]
  • [Cites] Blood. 1994 Jan 15;83(2):505-11 [8286748.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3097-105 [15251982.001]
  • [Cites] Electrophoresis. 2001 Oct;22(18):4016-22 [11700735.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):696-702 [11012982.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Cell. 1997 Mar 21;88(6):833-43 [9118226.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3928-41 [10805736.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Feb;117(1):71-9 [10700871.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3898-906 [16118316.001]
  • [Cites] Trends Biochem Sci. 1996 Jul;21(7):267-71 [8755249.001]
  • [Cites] Cell. 2004 May 14;117(4):515-26 [15137944.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Leukemia. 2003 Apr;17(4):738-45 [12682631.001]
  • [Cites] Cell. 1996 Nov 1;87(3):483-92 [8898201.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1627-32 [11587222.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9265-73 [15485896.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3793-9 [11739188.001]
  • (PMID = 17483057.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


49. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T: The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood; 2010 Nov 25;116(22):4578-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Ataxia Telangiectasia Mutated (ATM) gene is frequently inactivated in lymphoid malignancies such as chronic lymphocytic leukemia (CLL), T-prolymphocytic leukemia (T-PLL), and mantle cell lymphoma (MCL) and is associated with defective apoptosis in response to alkylating agents and purine analogues.
  • We investigated in vitro sensitivity to the poly (ADP-ribose) polymerase inhibitor olaparib (AZD2281) of 5 ATM mutant lymphoblastoid cell lines (LCL), an ATM mutant MCL cell line, an ATM knockdown PGA CLL cell line, and 9 ATM-deficient primary CLLs induced to cycle and observed differential killing compared with ATM wildtype counterparts.
  • A nonobese diabetic/severe combined immunodeficient (NOD/SCID) murine xenograft model of an ATM mutant MCL cell line demonstrated significantly reduced tumor load and an increased survival of animals after olaparib treatment in vivo.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Phthalazines / therapeutic use. Piperazines / therapeutic use. Poly(ADP-ribose) Polymerase Inhibitors. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Animals. Ataxia Telangiectasia Mutated Proteins. Cell Line, Tumor. Cell Proliferation / drug effects. Cells, Cultured. DNA Damage / drug effects. Gene Knockdown Techniques. Humans. Mice. Mice, SCID. Mutation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20739657.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G9901249; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Phthalazines; 0 / Piperazines; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; WOH1JD9AR8 / olaparib
  •  go-up   go-down


50. de Oliveira FM, Tone LG, Simões BP, Rego EM, Marinato AF, Jácomo RH, Falcão RP: Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia. Int J Lab Hematol; 2009 Aug;31(4):453-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell prolymphocytic leukemia.
  • We report a case of T-cell prolymphocytic leukemia (T-PLL) in a 41-year-old male.
  • Classical cytogenetic, spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH) studies of a blood sample obtained at diagnosis revealed the co-existence of t(X;14)(q28;q11), t(Y;14)(q12;q11) and a ring chromosome derived from i(8)(q10).
  • Immunophenotypic studies revealed involvement of T-cell lineage, with proliferation of CD4(-) CD8+.
  • Chromosomal instability associated with the disease progression may have allowed the emergence of cell clones with translocations involving the sex chromosomes and the ring chromosome observed.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, X / genetics. Chromosomes, Human, Y / genetics. Leukemia, Prolymphocytic, T-Cell / genetics. Ring Chromosomes. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294235.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Wanko SO, de Castro C: Hairy cell leukemia: an elusive but treatable disease. Oncologist; 2006 Jul-Aug;11(7):780-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hairy cell leukemia: an elusive but treatable disease.
  • Hairy cell leukemia (HCL) is a unique chronic lymphoproliferative disorder that can mimic or coexist with other clonal hematologic disorders and has been associated with autoimmune disorders.
  • It should be entertained as an alternative diagnosis in patients with cytopenias being assigned the diagnosis of aplastic anemia, hypoplastic myelodysplastic syndrome, atypical chronic lymphocytic leukemia, B-prolymphocytic leukemia, or idiopathic myelofibrosis.
  • The typical presentation is that of a middle-aged man with an incidental finding of pancytopenia, splenomegaly, and inaspirable bone marrow.
  • Relapsed disease after a prolonged remission can often be successfully retreated with the same initial agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / pathology. Leukemia, Hairy Cell / therapy

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880237.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; 9008-11-1 / Interferons
  •  go-up   go-down


52. Kikuchi T, Katayama Y, Kubonishi S, Watanabe T, Watanabe Y, Matsuoka K, Maeda Y, Namba N, Masunari T, Nasu R, Ikeda K, Tanimoto M: Chronic lymphoproliferative disorder with regulatory T-cell phenotype. Am J Hematol; 2006 Sep;81(9):713-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphoproliferative disorder with regulatory T-cell phenotype.
  • We report a case of T-cell chronic lymphoproliferative disorder (CLPD) that shows neither features of T-cell prolymphocytic leukemia nor disease progression for more than 34 months.
  • [MeSH-minor] Aged. Antigens, CD / biosynthesis. Biomarkers / blood. Cell Differentiation. Chronic Disease. Female. Forkhead Transcription Factors / biosynthesis. Humans. Microscopy, Electron, Transmission. Phenotype. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16838340.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


53. Abraham S, Braun RP, Matthes T, Saurat JH: A follow-up: previously reported apparent lymphomatoid contact dermatitis, now followed by T-cell prolymphocytic leukaemia. Br J Dermatol; 2006 Sep;155(3):633-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A follow-up: previously reported apparent lymphomatoid contact dermatitis, now followed by T-cell prolymphocytic leukaemia.
  • [MeSH-major] Dermatitis, Allergic Contact / diagnosis. Eyelid Diseases / diagnosis. Leukemia, Prolymphocytic / diagnosis. Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Fatal Outcome. Female. Humans. Leukemic Infiltration / diagnosis. Pseudolymphoma / diagnosis. Skin / pathology

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Dermatol. 2000 Aug;143(2):411-4 [10951155.001]
  • (PMID = 16911299.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


54. Loisel S, Ster KL, Quintin-Roue I, Pers JO, Bordron A, Youinou P, Berthou C: Establishment of a novel human B-CLL-like xenograft model in nude mouse. Leuk Res; 2005 Nov;29(11):1347-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a novel human B-CLL-like xenograft model in nude mouse.
  • We have developed a novel murine model for B-CLL by engrafting human prolymphocytic leukemia (PLL) or B-CLL cell line cells (JVM-3 and MEC-2 cell lines, respectively) into nude mice.
  • [MeSH-major] Disease Models, Animal. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Xenograft Model Antitumor Assays / methods
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Line, Tumor. Cell Proliferation. Female. Flow Cytometry / methods. Histological Techniques / methods. Humans. Immunophenotyping. Male. Mice. Mice, Nude. Sex Factors. Survival Rate. Transplantation, Heterologous

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896841.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


55. Mod H, Prasiko G, Jha AK, Chaurasia PP, Srivastava R: Radiotherapy for splenomegaly. JNMA J Nepal Med Assoc; 2005 Jul-Sep;44(159):97-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Massive splenomegaly may be seen in CML, CLL, hairy cell leukemia and splenic marginal zone lymphomas, prolymphocytic leukemia, myeloproliferative disorders such as polycythaemia rubra, polycythaemia vera or essential thrombocytosis or myelofibrosis.
  • [MeSH-major] Brachytherapy. Palliative Care. Primary Myelofibrosis / diagnosis. Splenomegaly / radiotherapy

  • Genetic Alliance. consumer health - Splenomegaly.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554863.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


56. Absi A, Hsi E, Kalaycio M: Prolymphocytic leukemia. Curr Treat Options Oncol; 2005 May;6(3):197-208
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukemia.
  • Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features.
  • T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy.
  • We recommend alemtuzumab as initial therapy and offer stem cell transplant (SCT) to selected young, healthy patients who respond.
  • Although B-cell prolymphocytic leukemia is also a progressive disease, some patients can achieve a prolonged progression-free-survival with fludarabine.
  • Rituximab is a promising agent and further investigations are warranted to better define its role in treatment of this disorder.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, B-Cell / therapy. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / administration & dosage. Female. Humans. Male. Pentostatin / administration & dosage. Rituximab. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):169-79 [10194135.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):145-7 [14508807.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):230-1 [10706770.001]
  • [Cites] Eur J Haematol. 2001 Feb;66(2):137-9 [11168523.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Acta Haematol. 1999;102(2):94-8 [10529513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51 [10077617.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):571-81 [11293906.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3885-9 [9520462.001]
  • [Cites] Eur J Haematol. 1996 Apr;56(4):235-40 [8641392.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):220-7 [15072613.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):724-32 [9074412.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Aug;55(1):1-9 [1913594.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):570-4 [7884417.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):37-43 [8996122.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1155-9 [9334731.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Ann Hematol. 2004 May;83(5):319-21 [15060751.001]
  • [Cites] Am J Hematol. 1992 May;40(1):71-2 [1566752.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):391-4 [14663643.001]
  • [Cites] Semin Oncol. 1990 Oct;17(5 Suppl 8):66-70 [1699285.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3555-61 [14506141.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):46-50 [9020373.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):371-5 [8704689.001]
  • [Cites] Eur J Haematol. 1992 Jul;49(1):46-7 [1499697.001]
  • [Cites] Hematol Pathol. 1987;1(1):27-33 [3509770.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1305-11 [9264385.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1821 [1357112.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Anticancer Drugs. 2001 Jun;12 Suppl 2:S15-9 [11508932.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):981-7 [11697653.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):6088-99 [7890742.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):617-9 [9054672.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1284-5 [7738636.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):580 [8790162.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):175-88 [1702143.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):157-9 [8611452.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):149-51 [11908720.001]
  • [Cites] Jpn J Clin Oncol. 1998 Apr;28(4):267-9 [9657013.001]
  • [Cites] Ann Hematol. 1998 Feb;76(2):85-6 [9540763.001]
  • [Cites] Cancer Treat Res. 1993;64:105-19 [7680874.001]
  • [Cites] Clin Lymphoma. 2002 Sep;3(2):105-10 [12435283.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):114-20 [12491512.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • (PMID = 15869731.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 54
  •  go-up   go-down


57. Belov L, Huang P, Chrisp JS, Mulligan SP, Christopherson RI: Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. J Immunol Methods; 2005 Oct 20;305(1):10-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells.
  • We have developed a microarray (DotScan) that enables rapid immunophenotyping and classification of leukaemias and lymphomas by measuring the capture of cells by immobilized dots of 82 CD antibodies [Belov, L., de la Vega, O., dos Remedios, C.G., Mulligan, S.P., 2001.
  • Immunophenotyping of leukemia using a cluster of differentiation antibody microarray. Cancer Res.
  • Identification of repertoires of surface antigens on leukemias using an antibody microarray.
  • After blocking the remaining nitrocellulose surface, individual arrays were incubated with each of 7 cell types from a human leukaemia cell panel consisting of three cell lines, CCRF-CEM (a T-cell acute lymphocytic leukaemia), MEC-1 (derived from B-cell chronic lymphocytic leukaemia) and HL-60 (a promyelocytic leukaemia), and four leukaemias from patients: a T-cell prolymphocytic leukaemia, a B-cell chronic lymphocytic leukaemia, and two acute myeloid leukaemias.
  • Leukaemia cells were captured by those immobilized antibodies for which they expressed the corresponding surface molecule.
  • The data obtained show the unique expression profiles of the 7 cell types in the leukaemia cell panel obtained with the DotScan microarray, and the differential capture patterns for these 7 cell types screened against the 498 antibodies in the HLDA8 microarray constructed for this study.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antigens, CD / analysis. Leukemia / classification. Protein Array Analysis / methods
  • [MeSH-minor] Cell Line, Tumor. Collodion / chemistry. Flow Cytometry. Humans. Leukemia, B-Cell / classification. Leukemia, B-Cell / immunology. Leukemia, Myeloid / classification. Leukemia, Myeloid / immunology. Leukemia, T-Cell / classification. Leukemia, T-Cell / immunology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Nitrocellulose .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125720.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 9004-70-0 / Collodion
  •  go-up   go-down


58. Ibrahim RB, Abidi MH, Al-Kadhimi Z, Uberti JP, Edwards DJ: Tacrolimus disposition in the ascitic fluid of a bone marrow transplant patient. Ann Pharmacother; 2010 May;44(5):939-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tacrolimus disposition in the ascitic fluid of a bone marrow transplant patient.
  • [MeSH-major] Ascitic Fluid / chemistry. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / pharmacokinetics. Leukemia, Prolymphocytic, T-Cell / therapy. Tacrolimus / pharmacokinetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371750.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


59. Mahmoud IS, Sughayer MA, Mohammad HA, Awidi AS, EL-Khateeb MS, Ismail SI: The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer; 2008 Aug 5;99(3):488-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias.
  • Despite the major role of the AKT/PKB family of proteins in the regulation of many growth and survival mechanisms in the cell, and the increasing evidence suggesting that AKT disruption could play a key role in many human malignancies, no major mutations of AKT genes had been reported, until very recently when Carpten et al reported a novel transforming mutation (E17K) in the pleckstrin homology domain of the AKT1 gene in solid tumours.
  • Considering the importance of the PI3K/AKT pathway in mediating survival and antiapoptotic signals in the B-cell types of chronic lymphocytic leukaemia (CLL) and acute lymphoblastic leukaemia (ALL), we sequenced the AKT1 exon 3 for the above mentioned mutation in 87 specimens, representing 45 CLLs, 38 ALLs and 4 prolymphocytic leukaemia (PLL) cases, which are all of B-cell origin.
  • We conclude that this mutation is not a major event in B-cell-derived lymphoid leukaemias.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Transformation, Neoplastic / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Promyelocytic, Acute / genetics. Point Mutation. Proto-Oncogene Proteins c-akt / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5 [11572954.001]
  • [Cites] Cell Signal. 2002 May;14(5):381-95 [11882383.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2969-76 [11929788.001]
  • [Cites] Leuk Lymphoma. 2002 Aug;43(8):1663-71 [12400610.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 11;1697(1-2):3-16 [15023346.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):733-42 [15158095.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3892-9 [15172999.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1391-400 [15175625.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Jul;74(7):3065-7 [197531.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1259-64 [2832508.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4820-7 [15728130.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):273-85 [15986137.001]
  • [Cites] Adv Cancer Res. 2005;94:29-86 [16095999.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7435-42 [16288290.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7455-64 [16288292.001]
  • [Cites] Oncology. 2006;70(4):285-9 [17047397.001]
  • [Cites] J Leukoc Biol. 2006 Dec;80(6):1473-9 [16940331.001]
  • [Cites] Leukemia. 2007 Jan;21(1):110-20 [17024114.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Nature. 2007 Jul 26;448(7152):439-44 [17611497.001]
  • [Cites] Ann Diagn Pathol. 2007 Oct;11(5):363-89 [17870025.001]
  • [Cites] Cytogenet Genome Res. 2007;118(2-4):310-9 [18000385.001]
  • [Cites] Blood. 2008 Jan 15;111(2):846-55 [17928528.001]
  • [Cites] Br J Haematol. 2008 Feb;140(3):344-7 [18053070.001]
  • [Cites] Acta Neuropathol. 2008 Mar;115(3):367-8 [18172656.001]
  • [Cites] Cell Cycle. 2008 Mar 1;7(5):665-9 [18256540.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1533-5 [18392055.001]
  • [Cites] Br J Haematol. 2008 May;141(5):742-3 [18410456.001]
  • (PMID = 18665177.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2527790
  •  go-up   go-down


60. Okamura K, Ikeda T, Shimakura Y, Yoshiba F, Kishi K, Ando K, Hotta T: [Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia]. Rinsho Ketsueki; 2005 Jul;46(7):527-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia].
  • Leukocyte count at diagnosis was 17,900/microl with 58% atypical lymphocytes having a convoluted nucleus and prominent nucleoli.
  • The patient was treated with Ara-C and etoposide before conditioning to decrease the high leukemia burden.
  • Because 9.4% of residual recipient type T-cells was seen with STR analysis on day 22, we decreased the dose of Cs'A.
  • After the occurrence of mild acute GVHD, the residual T-cell number decreased.
  • [MeSH-major] Bone Marrow Transplantation. Graft vs Leukemia Effect. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Graft vs Host Disease / prevention & control. Humans. Remission Induction. Transplantation Conditioning. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440747.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


61. Del Giudice I, Osuji N, Dexter T, Brito-Babapulle V, Parry-Jones N, Chiaretti S, Messina M, Morgan G, Catovsky D, Matutes E: B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia; 2009 Nov;23(11):2160-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic, B-Cell / genetics


62. Boyd K, Dearden CE: Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Rev Anticancer Ther; 2008 Apr;8(4):525-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antibody target is CD52, an antigen expressed on normal lymphocytes as well as many T- and B-cell neoplasms.
  • It therefore has a potential broad application across a spectrum of B- and T-cell malignancies as well as use as an immunosuppressant drug in, for example, bone marrow transplantation.
  • The original licensing in the USA and Europe was for the treatment of fludarabine-refractory chronic lymphocytic leukemia (CLL).
  • It seems to be particularly useful in patients with CLL who have deletion of the TP53 tumor suppressor gene, a subset of disease that responds poorly to other currently available chemotherapeutics.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antigens, CD / immunology. Antigens, Neoplasm / immunology. Drug Resistance, Neoplasm. Glycoproteins / immunology. Humans. Immunotherapy. Leukemia, Prolymphocytic, T-Cell / drug therapy. Leukemia, Prolymphocytic, T-Cell / immunology. Lymphoma, T-Cell, Cutaneous / drug therapy. Lymphoma, T-Cell, Cutaneous / immunology. Skin Neoplasms / drug therapy. Skin Neoplasms / immunology. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402519.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 3A189DH42V / alemtuzumab
  • [Number-of-references] 57
  •  go-up   go-down


63. Ishigaki T, Sasaki K, Watanabe K, Nakamura N, Toyota S, Kobayashi H, Tohda S: Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case. Cancer Genet Cytogenet; 2010 Aug;201(1):62-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case.
  • The IGH/CCND1 fusion gene has been reported in many hematologic tumors such as mantle cell lymphoma, chronic lymphocytic leukemia, prolymphocytic leukemia, multiple myeloma, and plasma cell leukemia.
  • We report a case of plasma cell leukemia showing five IGH/CCND1 fusion signals by interphase fluorescence in situ hybridization (FISH).
  • The amplification of the IGH/CCND1 fusion gene may contribute to the aggressive course of the disease.
  • To our knowledge, this is the first case showing amplification of the IGH/CCND1 gene in plasma cell neoplasms.
  • [MeSH-major] Cyclin D1 / genetics. Immunoglobulin Heavy Chains / genetics. Leukemia, Plasma Cell / genetics

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20633772.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Immunoglobulin Heavy Chains; 136601-57-5 / Cyclin D1
  •  go-up   go-down


64. Duek A, Shvidel L, Braester A, Berrebi A: Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders. Isr Med Assoc J; 2006 Dec;8(12):828-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and immunologic aspects of B chronic lymphocytic leukemia associated with autoimmune disorders.
  • BACKGROUND: Autoimmune disorders often develop during the course of B chronic lymphocytic leukemia.
  • We evaluated the lymphocyte morphology, immunoglobulin G and beta-2-microglobulin serum levels and positivity of the CD38 and FMC7 markers, and compared these values with those of a matched CLL population without autoimmune disorder.
  • We found atypical prolymphocytic morphology in 22%, high expression of the activation antigens CD38 and/or FMC7 in 30%, and high level of immunoglobulin G (> 1000 mg/dl) and beta-2-microglobulin in 57% and 78% respectively.
  • When compared with a matched CLL population without an autoimmune disorder, these values were statistically significant.
  • CONCLUSIONS: Our data, which show activated lymphocyte morphology, high levels of IgG and beta-2-microglobulin, and increased expression of CD38 and/or FMC7 in a significant number of cases, suggest that some degree of activation of B cells may lead to the occurrence of an autoimmune disorder in CLL.
  • [MeSH-major] Autoimmune Diseases / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Isr Med Assoc J. 2006 Dec;8(12):864 [17214107.001]
  • (PMID = 17214095.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers; 0 / Immunoglobulin G; 0 / beta 2-Microglobulin; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


65. Nakashima H, Saito B, Ariizumi H, Matsuda I, Nakamaki T, Tomoyasu S: [Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia]. Rinsho Ketsueki; 2008 Dec;49(12):1619-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia].
  • We report a case of B-cell prolymphocytic leukemia (B-PLL) that was treated successfully with splenic irradiation (SI).
  • Peripheral blood showed hemoglobin level 9.8 g/dl and white blood cell count 38.1x10(9)/l with 91% atypical cells.
  • A diagnosis of B-PLL was made.
  • [MeSH-major] Leukemia, Prolymphocytic, B-Cell / radiotherapy. Spleen

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110524.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


66. Pamuk GE, Donmez S, Turgut B, Demir M, Vural O: Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol; 2005 Jan;78(1):81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antineoplastic Agents / adverse effects. Leukemia, Prolymphocytic / drug therapy. Thrombocytopenia / chemically induced

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Am J Hematol. 2004 Apr;75(4):263 [15054827.001]
  • (PMID = 15609288.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


67. Dai HP, Xue YQ, Zhang J, Wu YF, Pan JL, Wang Y, Shen J: Translocation t(2;8)(p12;q24) in two patients with B Cell chronic lymphocytic leukemia. Acta Haematol; 2008;120(4):232-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation t(2;8)(p12;q24) in two patients with B Cell chronic lymphocytic leukemia.
  • In this study, we report for the first time on 2 cases of chronic lymphocytic leukemia (CLL) with t(2;8).
  • They were diagnosed as having typical CLL (case 1) and CLL/prolymphocytic leukemia (case 2), respectively, based on morphology and immunophenotyping.
  • [MeSH-major] Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 8. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19246886.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


68. Nowak D, Le Toriellec E, Stern MH, Kawamata N, Akagi T, Dyer MJ, Hofmann WK, Ogawa S, Koeffler HP: Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. Haematologica; 2009 Apr;94(4):518-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy.
  • BACKGROUND: T-cell prolymphocytic leukemia is a rare aggressive lymphoproliferative disease with a mature T-cell phenotype and characteristic genomic lesions such as inv(14)(q11q34), t(14;14)(q11;q32) or t(X;14)(q28;q11), mutation of the ATM gene on chromosome 11 and secondary alterations such as deletions of chromosome 8p and duplications of 8q.
  • DESIGN AND METHODS: We analyzed malignant cells from 18 patients with T-cell prolymphocytic leukemia using high density 250K single nucleotide polymorphism arrays and molecular allelokaryotyping to refine understanding of known alterations and identify new target genes.
  • CONCLUSIONS: The first high density single nucleotide polymorphism array allelokaryotyping of T-cell prolymphocytic leukemia genomes added substantial new details about established alterations in this disease and moreover identified numerous new potential target genes in common breakpoints, deletions and regions of acquired uniparental disomy.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / genetics. Polymorphism, Single Nucleotide / genetics. Uniparental Disomy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioessays. 2000 May;22(5):452-9 [10797485.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):640-8 [16056259.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Sep;121(2):128-32 [11063795.001]
  • [Cites] Oncogene. 2000 Dec 18;19(55):6482-9 [11175364.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1517-8 [11243240.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):248-54 [11391795.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] JAMA. 2001 Nov 14;286(18):2308-14 [11710897.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3521-7 [15161711.001]
  • [Cites] Mol Cancer. 2003 Aug 20;2:29 [12971829.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2475-83 [8361760.001]
  • [Cites] Blood. 1994 Nov 15;84(10):3473-82 [7949101.001]
  • [Cites] BMC Genomics. 2005;6:180 [16351727.001]
  • [Cites] Biochem Soc Symp. 2006;(73):23-39 [16626284.001]
  • [Cites] Med Oncol. 2006;23(1):17-22 [16645226.001]
  • [Cites] Curr Opin Oncol. 2007 Jan;19(1):43-9 [17133111.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] Am J Hum Genet. 2007 Jul;81(1):114-26 [17564968.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jul;11(7):955-65 [17614763.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5017-22 [17297439.001]
  • [Cites] Curr Biol. 2007 Aug 7;17(15):1298-307 [17656095.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):439-53 [17707832.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2153-63 [17713554.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):414-8 [17996645.001]
  • [Cites] J Clin Exp Hematop. 2007 Nov;47(2):31-42 [18040143.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4406-16 [17846228.001]
  • [Cites] Oncogene. 2007 Dec 10;26(56):7741-8 [18066086.001]
  • [Cites] Oncogene. 2007 Dec 10;26(56):7749-58 [18066087.001]
  • [Cites] Blood. 2008 Jan 1;111(1):328-37 [17890451.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2321-8 [18073348.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1296-305 [18246537.001]
  • [Cites] Trends Biochem Sci. 2008 Mar;33(3):122-31 [18291658.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5166-71 [18362358.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] J Immunol. 2008 Aug 15;181(4):2620-5 [18684952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11921-6 [18697940.001]
  • [Cites] Science. 2007 Apr 27;316(5824):590-3 [17463287.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1155-9 [9334731.001]
  • [Cites] Annu Rev Genet. 1997;31:635-62 [9442910.001]
  • [Cites] Blood. 1998 May 15;91(10):3920-6 [9573030.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jun;103(2):110-6 [9614908.001]
  • [Cites] Immunol Lett. 2005 Feb 15;97(1):7-17 [15626471.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):162-74 [15826831.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] Blood. 2000 Jul 1;96(1):374-6 [10939806.001]
  • (PMID = 19278963.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2663615
  •  go-up   go-down


69. Diop S, Letestu R, Orsolani D, Leboeuf Y, Le Tutour P, Thiam D, Diakhate L, Valensi F: [Expression of proliferation marker Ki 67 in chronic lymphocytic leukemia]. Dakar Med; 2005;50(2):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation marker Ki 67 in chronic lymphocytic leukemia].
  • [Transliterated title] Expression du marqueur de proliferation Ki 67 dans les leucemies lymphoides chroniques.
  • Chronic lymphocytic leukemia (CLL) is characterized by a clonal expansion of low proliferating mature B and T lymphocytes in the bone marrow and peripheral blood.
  • The nuclear antigen Ki 67 is a protein detected in G1, S, G2 and M phases of the cell cycle, but not in G0, and thus, is a widely accepted proliferation marker of Human tumors.
  • Our results allows to characterize between CLL: one group which proliferation rate (percentage of Ki 67 positive cells) was equal or less than 2%, represented by 14 cases (29,2%) with morphological aspect of typical CLL, one group which proliferation rate was between 3% and 9% represented by 32 cases (66,6%) with morphological aspect of polymorph CLL or prolymphocytic leukemia, and a last group with proliferation rate equal or up to 10% and corresponding to two cases (4,2%) of transformation of CLL to high grade Non Hodgkin lymphoma.
  • These data reinforce the notion that CLL is a disease with heterogeneity in clinical behavior, immunophenotype, cytogenetic, molecular aspects, and thus, prognostic.
  • [MeSH-major] Ki-67 Antigen / blood. Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / blood. B-Lymphocytes / immunology. Biomarkers. Cell Division. Female. Flow Cytometry. Humans. Lymphocyte Activation. Male. Middle Aged. Retrospective Studies. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16295759.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Senegal
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


70. Morris JC, Waldmann TA: Antibody-based therapy of leukaemia. Expert Rev Mol Med; 2009;11:e29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibody-based therapy of leukaemia.
  • Over the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma.
  • Currently, only two monoclonal antibodies - the anti-CD33 immunotoxin gemtuzumab ozogamicin and the CD52-directed antibody alemtuzumab - are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively.
  • Although not approved for such treatment, alemtuzumab is also active against T cell prolymphocytic leukaemia, cutaneous T cell lymphoma and Sézary syndrome, and adult T cell leukaemia and lymphoma.
  • In addition, rituximab has demonstrated activity against B cell chronic lymphocytic and hairy cell leukaemia.
  • Monoclonal antibodies targeting CD4, CD19, CD20, CD22, CD23, CD25, CD45, CD66 and CD122 are now being studied in the clinic for the treatment of leukaemia.
  • Improved interactions with Fc receptors on immune effector cells can enhance destruction of target cells through antibody-dependent cellular cytotoxicity and complement-mediated cell lysis.
  • The antibodies can also be armed with cellular toxins or radionuclides to enhance the destruction of leukaemia cells.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hematologic Neoplasms / therapy. Immunologic Factors / therapeutic use. Immunotoxins / therapeutic use. Leukemia / therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788782.001).
  • [ISSN] 1462-3994
  • [Journal-full-title] Expert reviews in molecular medicine
  • [ISO-abbreviation] Expert Rev Mol Med
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Immunologic Factors; 0 / Immunotoxins
  • [Number-of-references] 193
  •  go-up   go-down


71. Abbi KK, Rizvi SM, Sivik J, Thyagarajan S, Loughran T, Drabick JJ: Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature. Leuk Res; 2010 Jul;34(7):e154-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Guillain-Barre Syndrome / chemically induced. Leukemia, Prolymphocytic, T-Cell / drug therapy

  • Genetic Alliance. consumer health - Guillain-Barre Syndrome.
  • MedlinePlus Health Information. consumer health - Guillain-Barre Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20362332.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 0 / Immunoglobulins, Intravenous; 3A189DH42V / alemtuzumab
  •  go-up   go-down


72. Takizawa M, Matsushima T, Yokohama A, Handa H, Tsukamoto N, Karasawa M, Murakami H, Nojima Y: [Unclassified mature T cell leukemia with cerebriform nuclei]. Rinsho Ketsueki; 2005 Jul;46(7):486-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unclassified mature T cell leukemia with cerebriform nuclei].
  • Adult T cell leukemia (ATL) and Sézary syndrome (SS) were ruled out because of the negative HTLV-1 test and the absence of skin lesions, respectively.
  • T-prolymphocytic leukemia (T-PLL), which is characterized by a marked increase in leukocytes having a CD7-phenotype and a progressive fatal course, was also excluded.
  • Recently, the TCL1 onco-protein has been shown to be overexpressed in progressive T-PLL but not in other mature T cell leukemias including Sézary syndrome.
  • In its morphology and phenotypes, our case resembled 'Sézary cell leukemia (SCL)' but the clinical course was much more indolent.
  • This case did not match any of the mature T cell leukemias defined in the WHO classification.
  • [MeSH-major] Cell Nucleus / ultrastructure. Leukemia, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440739.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / TCL1A protein, human
  •  go-up   go-down


73. Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, Brito-Babapulle V, Oscier D, Catovsky D: IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia; 2006 Jul;20(7):1231-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
  • B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis.
  • To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations, ZAP-70 and CD38 in 19 cases with de novo B-PLL.
  • [MeSH-major] Antigens, CD38 / genetics. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Membrane Glycoproteins / genetics. ZAP-70 Protein-Tyrosine Kinase / genetics

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642047.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Membrane Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


74. Vasilj A, Kojić-Katović S, Maricević I, Zokvić E, Kelcec IB, Tomas D, Curić-Jurić S: Hodgkin's lymphoma variant of Richter's syndrome. Coll Antropol; 2010 Mar;34(1):295-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic lymphocytic leukemia/small lymphocitic lymphoma (CLL/SLL) is low-grade malignant lymphoprolipheration, that has tendency to convert to a higher-grade neoplasm over time.
  • More common is the development of a diffuse large cell lymphoma or transformation into prolymphocytic cell population.
  • In rare cases, 0.1-0.5% of patients develop multiple myeloma or Hodgkin's disease.
  • On the basis of clinical simptoms, cytological, hystological and immunohistological finding in April 2008 CLL/SLL were diagnosed.
  • The diagnosis was Hodgkin's disease.
  • Immuno-hystological studies of the lymph node was consistent with type I Hodgkin's type of Richter's syndrome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Reed-Sternberg Cells / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437646.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


75. Meeuse JJ, Sprenger HG, van Assen S, Leduc D, Daenen SM, Arends JP, van der Werf TS: Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia. Emerg Infect Dis; 2007 Dec;13(12):1942-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.
  • [MeSH-major] Actinomycetales Infections / etiology. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / adverse effects. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Leukemia, Prolymphocytic, T-Cell / drug therapy. Rhodococcus equi

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Clin Infect Dis. 2002 May 15;34(10):1379-85 [11981734.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4):424-33 [12939711.001]
  • [Cites] Clin Infect Dis. 2006 Jul 1;43(1):16-24 [16758413.001]
  • [Cites] Emerg Infect Dis. 1997 Apr-Jun;3(2):145-53 [9204295.001]
  • [Cites] Vet Microbiol. 1997 Jun 16;56(3-4):167-76 [9226831.001]
  • [Cites] Clin Microbiol Rev. 1991 Jan;4(1):20-34 [2004346.001]
  • (PMID = 18258054.001).
  • [ISSN] 1080-6040
  • [Journal-full-title] Emerging infectious diseases
  • [ISO-abbreviation] Emerging Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  • [Other-IDs] NLM/ PMC2876741
  •  go-up   go-down


76. Jamet D, Quinio D, Moalic E, Ianotto JC, Dalbies F, Guillerm G, Marion V, Berthou C, Nevez G: [Systemic microsporidiosis and toxoplasmosis in a patient with T prolymphocytic leukemia]. Med Mal Infect; 2009 Jun;39(6):406-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic microsporidiosis and toxoplasmosis in a patient with T prolymphocytic leukemia].
  • [Transliterated title] Microsporidiose et toxoplasmose disséminées chez une patiente présentant une leucémie prolymphocytaire T.
  • We report a case of microsporidiosis in a 72-year-old woman presenting with prolymphocytic leukemia.
  • The underlying conditions 7 months after leukemia was diagnosed were pancytopenia and immunosuppression due to alemtuzumab and pentostatin.
  • The present case in a patient with lymphoid leukemia is the first to be reported.
  • [MeSH-major] Encephalitozoonosis / complications. Leukemia, Prolymphocytic, T-Cell / complications

  • Genetic Alliance. consumer health - Microsporidiosis.
  • Hazardous Substances Data Bank. ALBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046839.001).
  • [ISSN] 0399-077X
  • [Journal-full-title] Médecine et maladies infectieuses
  • [ISO-abbreviation] Med Mal Infect
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] F4216019LN / Albendazole
  •  go-up   go-down


77. Brüggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, Oeschger S, Jasani B, Ott M, Delsol G, Orfao A, Tiemann M, Herbst H, Langerak AW, Spaargaren M, Moreau E, Groenen PJ, Sambade C, Foroni L, Carter GI, Hummel M, Bastard C, Davi F, Delfau-Larue MH, Kneba M, van Dongen JJ, Beldjord K, Molina TJ: Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia; 2007 Feb;21(2):215-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.
  • Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in mature T-cell neoplasms.
  • To obtain reference values for Ig/TCR rearrangement patterns, 19 European laboratories investigated 188 T-cell malignancies belonging to five World Health Organization-defined entities.
  • TCR clonality was detected in 99% (143/145) of all definite cases of T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, peripheral T-cell lymphoma (unspecified) and angioimmunoblastic T-cell lymphoma (AILT), whereas nine of 43 anaplastic large cell lymphomas did not show clonal TCR rearrangements.
  • Our study indicates that the BIOMED-2 multiplex PCR tubes provide a powerful strategy for clonality assessment in T-cell malignancies assisting the firm diagnosis of T-cell neoplasms.
  • The detected TCR gene rearrangements can also be used as PCR targets for monitoring of minimal residual disease.
  • [MeSH-major] Genes, Immunoglobulin. Leukemia, T-Cell / genetics. Lymphoma, T-Cell / genetics. Polymerase Chain Reaction / methods. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Gene Amplification. Gene Rearrangement. Genotype. Humans. Immunohistochemistry. Leukemia, Prolymphocytic / genetics. Leukemia, Prolymphocytic / immunology. Leukemia, Prolymphocytic / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Large B-Cell, Diffuse / pathology. T-Lymphocytes / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17170730.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


78. Lau SK, Weiss LM, Zhang Y, Huang Q: Prolymphocytoid transformation of follicular lymphoma with coexpression of CD5 and CD10. Leuk Lymphoma; 2006 Mar;47(3):541-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic transformation of follicular lymphoma is usually to a diffuse large B-cell lymphoma.
  • We present a rare example of a histologic transformation of follicular lymphoma manifested by prolymphocytoid morphology and an unusual immunophenotype characterized by coexpression of CD5 and CD10.
  • Prolymphocytoid transformation, similar to other histologic forms of transformation of follicular lymphoma, appears to accompany clinical progression of disease.
  • [MeSH-major] Antigens, CD5 / biosynthesis. Cell Transformation, Neoplastic / pathology. Leukemia, Prolymphocytic / pathology. Lymphoma, Follicular / pathology. Neoplasms, Second Primary / pathology. Neprilysin / biosynthesis
  • [MeSH-minor] Adult. Disease Progression. Fatal Outcome. Female. Humans. Immunophenotyping. Remission Induction. Treatment Failure

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396778.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD5; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


79. Khot A, Dearden C: T-cell prolymphocytic leukemia. Expert Rev Anticancer Ther; 2009 Mar;9(3):365-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia.
  • T-cell prolymphocytic leukemia is a rare post-thymic lymphoid disorder, which has distinctive clinical, morphologic, immunophenotypic and cytogenetic features.
  • However, responses are transient and allogeneic hematopoietic progenitor-cell transplantation remains the only potential curative option.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / genetics. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / genetics. Antibodies, Neoplasm / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Drug Administration Schedule. Hematopoietic Stem Cell Transplantation. Humans. Prognosis. Stem Cell Transplantation. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275513.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  • [Number-of-references] 46
  •  go-up   go-down


80. Fidani L, Hatzitolios AI, Goulas A, Savopoulos C, Basayannis C, Kotsis A: Cholesteryl ester transfer protein TaqI B and lipoprotein lipase Ser447Ter gene polymorphisms are not associated with ischaemic stroke in Greek patients. Neurosci Lett; 2005 Aug 12-19;384(1-2):102-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholesteryl ester transfer protein (CETP) and lipoprotein lipase (LPL) are both key players in plasma lipoprotein homeostasis and, as such, genetically induced alterations in their respective activities may affect susceptibility to cerebrovascular diseases.
  • In this study, we examined the distribution of two common polymorphisms, namely CETP TaqI B and LPL Ser447Ter in a cohort of Greek clinically diagnosed late-onset ischaemic stroke patients (n = 98) and an ethnicity-, age- and sex-matched control group with no manifestations of vascular disease (n = 100).
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Cholesterol Ester Transfer Proteins. Female. Gene Frequency. Genetic Predisposition to Disease. Greece / epidemiology. Humans. Male. Odds Ratio

  • MedlinePlus Health Information. consumer health - Stroke.
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896905.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CETP protein, human; 0 / Carrier Proteins; 0 / Cholesterol Ester Transfer Proteins; 0 / Glycoproteins; 452VLY9402 / Serine; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


81. Babadoko AA, Hassan A, Ahmed AJ, Isah HA, Suleiman AM: Splenic lymphoma with villous lymphocytes: case report and literature review. Niger J Med; 2007 Jan-Mar;16(1):71-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Splenic lymphoma with villous lymphocytes (SLVL) is a rare but recognized distinct disease entity among chronic B lymphoproliferative disorders.
  • It is frequently misdiagnosed as chronic lymphocytic leukaemia, (CLL) Prolymphocytic leukaemia or Hairy Cell leukaemia.
  • METHOD: The case records of a sixty year old Nigerian male with a splenic lymphoma and a review of the literature on the subject using MEDLINE, other internet sources and manual library search was utilized.
  • CONCLUSION: Adequate morphologic evaluation is advocated particularly in the resource limited settings were Cytogenetics, immunohistochemistry and immunophenotyping are not available.
  • [MeSH-major] B-Lymphocytes / pathology. Lymphoma / diagnosis. Lymphoproliferative Disorders / diagnosis. Splenic Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17563973.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 9
  •  go-up   go-down


82. Curtin NJ, Schwarer AP: Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibility. Clin Lab Haematol; 2005 Jun;27(3):206-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmyeloablative peripheral blood stem cell transplant for T-cell prolymphocytic leukaemia complicated by fulminant haemolysis and acute renal failure at engraftment secondary to minor ABO incompatibility.
  • We present a 54-year-old man who underwent human leucocyte antigen-identical sibling nonmyeloablative peripheral blood stem cell transplant for primary refractory T-cell prolymphocytic leukaemia (T-PLL).
  • [MeSH-major] ABO Blood-Group System / adverse effects. Acute Kidney Injury / etiology. Blood Group Incompatibility / complications. Hematopoietic Stem Cell Transplantation / adverse effects. Hemolysis. Leukemia, Prolymphocytic / complications. Leukemia, T-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15938729.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


83. Herling M, Patel KA, Teitell MA, Konopleva M, Ravandi F, Kobayashi R, Jones D: High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood; 2008 Jan 1;111(1):328-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.
  • The T-cell leukemia 1 (TCL1) oncoprotein is overexpressed by chromosomal rearrangement in the majority of cases of T-cell prolymphocytic leukemia (T-PLL).
  • In vitro, TCL1 can modulate the activity of the serine-threonine kinase AKT, a downstream effector of T-cell receptor (TCR) signaling.
  • High-level TCL1 in TCR-expressing T-PLL is associated with higher presenting white blood cell counts, faster tumor cell doubling, and enhanced in vitro growth response to TCR engagement.
  • In primary tumors and TCL1-transfected T-cell lines, TCR engagement leads to rapid recruitment of TCL1 and AKT to transient membrane activation complexes that include TCR-associated tyrosine kinases, including LCK.
  • Pharmacologic inhibition of AKT activation alters the localization, stability, and levels of these transient TCL1-AKT complexes and reduces tumor cell growth.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3028-33 [10716693.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35890-902 [15169787.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2095-100 [10786666.001]
  • [Cites] Pathol Int. 2000 Mar;50(3):191-9 [10792782.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Lab Invest. 2001 Apr;81(4):555-64 [11304575.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115(6):885-92 [11392886.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):248-54 [11391795.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Pathobiology. 2001;69(2):59-66 [11752899.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3743-51 [11707444.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1513-25 [11839817.001]
  • [Cites] Biochemistry. 2002 May 21;41(20):6376-82 [12009899.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3369-73 [12384439.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14392-7 [12381789.001]
  • [Cites] Blood. 2003 Jun 15;101(12):5007-9 [12576313.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jun;85(11):3933-7 [2836865.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jan;86(2):602-6 [2783489.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Aug;55(1):1-9 [1913594.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Oncogene. 1993 Sep;8(9):2475-83 [8361760.001]
  • [Cites] J Biol Chem. 1994 Feb 18;269(7):5241-8 [8106507.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12530-4 [7809072.001]
  • [Cites] Blood. 1995 Aug 1;86(3):1163-9 [7620169.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1923-7 [8634440.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):580 [8790162.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):724-32 [9074412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3413-8 [9520380.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jun;103(2):110-6 [9614908.001]
  • [Cites] Blood. 1998 Jul 15;92(2):368-73 [9657733.001]
  • [Cites] Jpn J Cancer Res. 1998 Jul;89(7):712-8 [9738977.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):840 [10354157.001]
  • [Cites] Ann Oncol. 1999 Jun;10(6):649-53 [10442186.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9809-14 [10449776.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1288-94 [15479728.001]
  • [Cites] Leuk Res. 2005 Mar;29(3):253-62 [15661260.001]
  • [Cites] Mol Cancer Ther. 2005 Jun;4(6):977-86 [15956255.001]
  • [Cites] J Immunol. 2005 Jul 15;175(2):864-73 [16002684.001]
  • [Cites] Clin Lymphoma Myeloma. 2005 Nov;6(3):234-9 [16354329.001]
  • [Cites] Leukemia. 2006 Feb;20(2):280-5 [16341048.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10175-80 [17548807.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1123-9 [17592280.001]
  • [Cites] FASEB J. 2007 Aug;21(10):2273-84 [17360849.001]
  • (PMID = 17890451.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA90571; United States / NCI NIH HHS / CA / R01 CA107300; United States / NCI NIH HHS / CA / R01 CA090571; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / CA107300
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Receptors, Antigen, T-Cell; 0 / TCL1A protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2200815
  •  go-up   go-down


84. Magro CM, Morrison CD, Heerema N, Porcu P, Sroa N, Deng AC: T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. J Am Acad Dermatol; 2006 Sep;55(3):467-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
  • BACKGROUND: T-cell prolymphocytic leukemia (T-PLL), formerly categorized as T-cell chronic lymphocytic leukemia, is a rare and aggressive hematologic malignancy.
  • The disease was associated in all with skin involvement with facial preference; edema, purpura, and lesional symmetry were characteristic.
  • All expressed T-cell leukemia 1 (TCL-1) and CD7; cutaneous lymphocyte antigen expression was discernible in a dot-like perinuclear array.
  • In two cases tested, T-cell receptor beta rearrangements were observed.
  • Four patients died from their disease within 18 months of diagnosis.
  • CONCLUSION: T-PLL is a distinctive post-thymic T-cell malignancy with frequent cutaneous tropism.
  • A diagnosis is possible in almost all cases based on characteristic clinical, light microscopic, phenotypic, and cytogenetic features.
  • [MeSH-major] Leukemia, Prolymphocytic / pathology. Leukemia, Prolymphocytic, T-Cell / pathology. Skin / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Aneuploidy. Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / pathology. Cytogenetic Analysis. Face. Female. Gene Amplification. Gene Rearrangement. Glycoproteins / metabolism. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Phenotype. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-myc / genetics. Receptors, Antigen, T-Cell, alpha-beta / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2007 Sep;57(3):533-4 [17707160.001]
  • (PMID = 16908353.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / TCL1A protein, human
  •  go-up   go-down


85. Ravandi F, O'Brien S: Alemtuzumab. Expert Rev Anticancer Ther; 2005 Feb;5(1):39-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Over the past several years, a number of clinical trials have demonstrated the clinical activity of alemtuzumab in treating patients with chronic lymphocytic leukemia, T-cell malignancies such as T-prolymphocytic leukemia and cutaneous T-cell lymphoma, as well as in the prevention and therapy of graft-versus-host disease in the setting of allogeneic stem cell transplantation.

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757437.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / CD52 antigen; 0 / Glycoproteins; 3A189DH42V / alemtuzumab
  • [Number-of-references] 91
  •  go-up   go-down


86. Maljaei SH, Asvadi-E-Kermani I, Eivazi-E-Ziaei J, Nikanfar A, Vaez J: Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders. Indian J Med Sci; 2005 May;59(5):187-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders.
  • BACKGROUND: Although many B-cell chronic lymphoproliferative disorders (BCLPDs) including B-cell chronic lymphocytic leukemia (B-CLL) have characteristic clinical and biological features, the overlapping morphologic and immunophenotypic profiles of various BCLPDs, is still the main problem.
  • MATERIALS AND METHODS: The expression of CD45 in 37 patients with BCLPD including typical B-CLL (Group I), atypical B-CLL and CLL/PLL (II), and hairy cell leukemia (HCL), B-prolymphocytic leukemia (B-PLL), and B-non Hodgkin's lymphoma (B-NHL) as non-CLL BCLPDs (III) and in eight healthy age matched controls (IV) was quantitatively compared by flow cytometric CD45/RALS gating strategy.
  • [MeSH-major] Antigens, CD45 / immunology. Leukemia, B-Cell / diagnosis. Membrane Proteins / biosynthesis. Phosphoproteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. Biomarkers / blood. Diagnosis, Differential. Female. Flow Cytometry. Fluorescent Antibody Technique, Direct. Follow-Up Studies. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Prospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985726.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / PTPRCAP protein, human; 0 / Phosphoproteins; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


87. Marx A, Müller-Hermelink HK, Hartmann M, Geissinger E, Zettl A, Adam P, Rüdiger T: [Lymphomas of the spleen]. Pathologe; 2008 Mar;29(2):136-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exceptions include splenic marginal zone lymphomas and hepatosplenic T-cell lymphomas that are typically diagnosed from histological findings.
  • In addition, hairy-cell leukemia, LGL leukemia and T-cell prolymphocytic leukemia typically show characteristic patterns of infiltration in the spleen which may be diagnostically useful.
  • [MeSH-minor] Antigens, CD / analysis. Diagnosis, Differential. Humans. Leukemia, Hairy Cell / pathology. Leukemia, Prolymphocytic, T-Cell / pathology. Lymphoma, T-Cell / pathology. Splenectomy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Dec 15;102(13):4261-9 [12907441.001]
  • [Cites] Semin Diagn Pathol. 2003 May;20(2):105-20 [12945934.001]
  • [Cites] Histol Histopathol. 1990 Jan;5(1):113-22 [2134351.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):772-80 [9236833.001]
  • [Cites] Histopathology. 2002 Jan;40(1):22-30 [11903595.001]
  • [Cites] Semin Diagn Pathol. 2003 May;20(2):121-7 [12945935.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):935-41 [15958859.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):763-71 [12875995.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3828-34 [7949139.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1583-9 [10329610.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4265-74 [8943863.001]
  • [Cites] Semin Diagn Pathol. 2003 May;20(2):84-93 [12945932.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Am J Surg Pathol. 2000 Dec;24(12):1581-92 [11117778.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):81-8 [12107092.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):455-66 [1599024.001]
  • [Cites] Int J Surg Pathol. 2004 Jan;12(1):31-7 [14765270.001]
  • [Cites] Cancer. 2001 Jun 1;91(11):2001-9 [11391578.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):895-902 [12826881.001]
  • [Cites] Hum Pathol. 1989 Jan;20(1):62-8 [2912876.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] Leuk Lymphoma. 1994;14 Suppl 1:1-12 [7820038.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):757-65 [2504066.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):643-51 [2661408.001]
  • [Cites] Histopathology. 1998 Sep;33(3):230-9 [9777389.001]
  • (PMID = 18214484.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


88. Sohani AR, Ferry JA, Chang PS, Abramson JS: Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. J Clin Oncol; 2010 Feb 10;28(5):e69-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Neoplasm / adverse effects. Antineoplastic Agents / adverse effects. Herpesvirus 4, Human / isolation & purification. Leukemia, Prolymphocytic, T-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / chemically induced
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Examination. Disease Progression. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Treatment Failure

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917859.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


89. Tanvetyanon T, Elmishad AG, Carbone M: Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link? Anticancer Res; 2005 Jan-Feb;25(1B):429-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?
  • A patient with a history of heavy asbestos exposure presented with B-prolymphocytic leukemia/lymphoma (B-PLL).
  • Since asbestos, simian virus 40 (SV40), or both have been associated with lymphoproliferative disease and mesothelioma, we investigated both possible links in our patient.
  • [MeSH-major] Asbestos / adverse effects. Leukemia, Prolymphocytic / pathology. Lung Neoplasms / etiology. Lung Neoplasms / secondary. Mesothelioma / etiology. Mesothelioma / secondary. Simian virus 40 / metabolism. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. Blotting, Southern. Bone Marrow / metabolism. DNA Primers / chemistry. DNA, Viral / metabolism. Disease Progression. Humans. Immunosuppressive Agents / pharmacology. Male. Polymerase Chain Reaction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816607.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA92657
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Viral; 0 / Immunosuppressive Agents; 1332-21-4 / Asbestos; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


90. Lan K, Murakami M, Choudhuri T, Tsai DE, Schuster SJ, Wasik MA, Robertson ES: Detection of Epstein-Barr virus in T-cell prolymphocytic leukemia cells in vitro. J Clin Virol; 2008 Nov;43(3):260-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of Epstein-Barr virus in T-cell prolymphocytic leukemia cells in vitro.
  • BACKGROUND: Epstein-Barr virus (EBV) is closely associated with the development of a number of tumors.
  • During latent infection, EBV continuously expresses a number of viral genes which are essential for cell transformation and maintenance of the malignant phenotype of EBV-related tumors.
  • There has been no previous link between EBV and T-cell prolymphocytic leukemia (T-PLL), a distinctive form of leukemia derived from T-cells at an intermediate stage of differentiation between a cortical thymocyte and a mature peripheral blood T-cell.
  • STUDY DESIGN: T-PLL cells were isolated from the peripheral blood of a patient diagnosed with T-PLL and continuously cultured for about 1 year.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790666.001).
  • [ISSN] 1386-6532
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA174439; United States / NCI NIH HHS / CA / R01 CA091792; United States / NIDCR NIH HHS / DE / R01 DE014136; United States / NIDDK NIH HHS / DK / P30 DK050306; United States / NIDCR NIH HHS / DE / DE014136-04; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / R01 CA177423; United States / NCI NIH HHS / CA / R01 CA108461; United States / NCI NIH HHS / CA / CA072510
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS78635; NLM/ PMC4289600
  •  go-up   go-down


91. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M: Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant; 2010 Apr;16(4):543-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.
  • The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT).
  • Further study of a larger population of patients is needed to determine which patients are more likely to benefit.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Semin Oncol. 1990 Oct;17(5 Suppl 8):66-70 [1699285.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1710-6 [7655003.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):114-20 [12491512.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):149-51 [11908720.001]
  • [Cites] JAMA. 2001 Nov 14;286(18):2308-14 [11710897.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5638-43 [11607815.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Eur J Haematol. 2001 Feb;66(2):137-9 [11168523.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Nov;5(11):882-4; discussion 884 [18185486.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2153-63 [17713554.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(4):795-810 [16997184.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(12):1225 [15880130.001]
  • [Cites] Curr Treat Options Oncol. 2005 May;6(3):197-208 [15869731.001]
  • [Cites] Bone Marrow Transplant. 1998 Mar;21(6):627-8 [9580345.001]
  • [Cites] Ann Hematol. 1998 Feb;76(2):85-6 [9540763.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):391-4 [14663643.001]
  • (PMID = 19961946.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-12; United States / NCI NIH HHS / CA / U24 CA76518; United States / NHLBI NIH HHS / HL / U01 HL069294; United States / NCI NIH HHS / CA / CA076518-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS162699; NLM/ PMC2839005
  •  go-up   go-down


92. Gallipoli P, Clark A, Leach M: The evolving management of a rare lymphoproliferative disorder-T-cell prolymphocytic leukemia. Am J Hematol; 2009 Nov;84(11):750-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The evolving management of a rare lymphoproliferative disorder-T-cell prolymphocytic leukemia.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19714590.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Malani AK, Gupta C, Rangineni R, Singh J, Ammar H: Concomitant presentation of acute myeloid leukemia with T-cell large granular lymphocytic leukemia. Acta Oncol; 2007;46(2):247-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant presentation of acute myeloid leukemia with T-cell large granular lymphocytic leukemia.
  • T-cell large granular lymphocyte leukemia (T-LGL) also known as T-cell chronic lymphocytic leukemia is rare and comprises a small minority of all small lymphocytic leukemias.
  • The concomitant presentation of T-LGL with acute myeloid leukemia (AML) has not been previously reported.
  • We present an elderly gentleman with concomitant T-LGL and AML (non-M3) diagnosed by a combination of morphologic evaluation, immunophenotyping by flow cytometry, and T-cell gene rearrangement studies.
  • He remains alive and well seven months after initial diagnosis.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Leukemia, Prolymphocytic, T-Cell / diagnosis
  • [MeSH-minor] Acute Disease. Aged, 80 and over. Antigens, CD / analysis. Flow Cytometry. Humans. Male

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453377.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 17
  •  go-up   go-down


94. Mikaelsson E, Danesh-Manesh AH, Lüppert A, Jeddi-Tehrani M, Rezvany MR, Sharifian RA, Safaie R, Roohi A, Osterborg A, Shokri F, Mellstedt H, Rabbani H: Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood; 2005 Jun 15;105(12):4828-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.
  • Fibromodulin is an extracellular matrix protein normally produced by collagen-rich tissues; the fibromodulin gene has been found to be the most overexpressed gene in B-cell chronic lymphocytic leukemia.
  • In this study, fibromodulin was expressed at the gene level (reverse transcription-polymerase chain reaction [RT-PCR]) in all patients with B-CLL (n = 75) and in most (5 of 7) patients with mantle cell lymphoma (MCL).
  • Fibromodulin was also detected at the protein level in the cytoplasm of the B-CLL cells and in the supernatant after in vitro cultivation, but not at the cell surface.
  • Fibromodulin was not found in patients with T-cell chronic lymphocytic leukemia (T-CLL), B-cell prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), hairy cell leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), or chronic myelogenous leukemia (CML) or in 36 hematologic cell lines.
  • [MeSH-major] Extracellular Matrix / metabolism. Extracellular Matrix Proteins / chemistry. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, Mantle-Cell / metabolism. Proteoglycans / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / biosynthesis. Antigens, CD19 / biosynthesis. Antigens, CD5 / biosynthesis. Antigens, Differentiation, T-Lymphocyte / biosynthesis. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Line, Transformed. Cell Line, Tumor. Coculture Techniques. Collagen / metabolism. Cytoplasm / metabolism. DNA Mutational Analysis. DNA, Complementary / metabolism. Female. Fibroblasts / metabolism. Flow Cytometry. Hematologic Neoplasms / metabolism. Humans. Immunoblotting. Lectins, C-Type. Leukemia, T-Cell / metabolism. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Mutation. Palatine Tonsil / metabolism. RNA, Messenger / metabolism. Receptors, Interleukin-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tetradecanoylphorbol Acetate / pharmacology. Time Factors

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741214.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD5; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / CD69 antigen; 0 / DNA, Complementary; 0 / Extracellular Matrix Proteins; 0 / Lectins, C-Type; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / Receptors, Interleukin-2; 126468-95-9 / fibromodulin; 9007-34-5 / Collagen; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


95. Jahanmehr SA, Rogers M, Zheng J, Lai R, Wang C: Quantitation of cytological parameters of malignant lymphocytes using computerized image analysis. Int J Lab Hematol; 2008 Aug;30(4):278-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, image analysis program was used to quantitate cytological parameters of lymphocytes in B-cell lymphoproliferative disorders.
  • Chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and B-cell prolymphocytic leukemia (B-PLL) were selected to represent typically small, medium, and large-sized lymphocytes, respectively.
  • A set of measurements was generated for quantitation of total cell area, cell diameter, cytoplasm area, nuclear area, nuclear/cell ratio, and nuclear density.
  • The results from image analysis may assist in defining morphological criteria and in developing quantitative cell morphology.
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Prolymphocytic, B-Cell / pathology. Lymphoma, Mantle-Cell / pathology. Microscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665824.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


96. Friedenson B: The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer; 2007;7:152
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study was designed to test the hypothesis that inactivation of virtually any component within the pathway containing the BRCA1 and BRCA2 proteins would increase the risks for lymphomas and leukemias.
  • These kinds of rearrangements are typically associated with some lymphomas and leukemias.
  • RESULTS: Deleterious mutations of genes encoding proteins virtually anywhere within the BRCA pathway increased risks up to nearly 2000 fold for certain leukemias and lymphomas.
  • Cancers with large increases in risk included mantle cell lymphoma, acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, and prolymphocytic leukemia.
  • Mantle cell lymphoma is defined by a characteristic rearrangement of DNA fragments interchanged between chromosomes 11 and 14.
  • CONCLUSION: An important function of the BRCA pathway is to prevent a subgroup of human leukemias and lymphomas that may involve non-random, characteristic gene rearrangements.
  • Inactivation of a single gene within the pathway can increase risks for multiple cancers and inactivation of a different gene in the same pathway may have similar effects.
  • [MeSH-minor] Adult. Child. Fanconi Anemia / genetics. Female. Genetic Predisposition to Disease. Humans. Leukemia / genetics. Lymphoma / genetics. Male. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4259-64 [11106241.001]
  • [Cites] J Clin Epidemiol. 2000 Nov;53(11):1119-29 [11106885.001]
  • [Cites] Am J Hum Genet. 2001 Mar;68(3):700-10 [11179017.001]
  • [Cites] EMBO J. 2003 Nov 3;22(21):5806-16 [14592978.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8717-25 [14695186.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3226-9 [15070707.001]
  • [Cites] Blood. 2004 Jul 15;104(2):350-5 [15059844.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Nov;41(3):257-65 [15334549.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2007-15 [15370245.001]
  • [Cites] J Natl Cancer Inst. 1985 Aug;75(2):207-17 [3860679.001]
  • [Cites] Mol Cell. 1998 Feb;1(3):347-57 [9660919.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):175-82 [9739021.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] Leukemia. 1999 Mar;13(3):460-8 [10086737.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17108-13 [15563594.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1288-92 [15798766.001]
  • [Cites] Development. 2005 May;132(10):2263-72 [15829516.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):435-40 [11161413.001]
  • [Cites] Nat Immunol. 2000 Jul;1(1):77-82 [10881179.001]
  • [Cites] Nature. 2001 May 17;411(6835):336-41 [11357140.001]
  • [Cites] J Clin Pathol. 2001 Jul;54(7):512-6 [11429421.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38549-54 [11504724.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):758-9 [11745474.001]
  • [Cites] Blood. 2002 Jan 1;99(1):300-9 [11756185.001]
  • [Cites] Cell. 2002 Jan 25;108(2):171-82 [11832208.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):502-13 [12094236.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65 [12237281.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Nov;35(3):204-18 [12353263.001]
  • [Cites] Nat Cell Biol. 2002 Nov;4(11):865-70 [12402044.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4602-8 [12393693.001]
  • [Cites] Oncogene. 2002 Dec 16;21(58):8967-80 [12483513.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):425-40 [12518367.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1249-56 [12393516.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):289-94 [12692102.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1917-9 [12736286.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4247-56 [12773567.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4975-81 [12609845.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Science. 2003 Oct 24;302(5645):643-6 [14576434.001]
  • [Cites] Br J Haematol. 2005 May;129(4):520-30 [15877734.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):813-22 [15928302.001]
  • [Cites] Nat Genet. 2005 Sep;37(9):931-3 [16116424.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6364-9 [16155021.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):255-65 [16153896.001]
  • [Cites] MedGenMed. 2005;7(2):60 [16369438.001]
  • [Cites] Mol Endocrinol. 2006 Jan;20(1):14-34 [16109739.001]
  • [Cites] Nucleic Acids Res. 2006;34(5):1416-26 [16522651.001]
  • [Cites] JAMA. 2006 Mar 22;295(12):1379-88 [16551709.001]
  • [Cites] Nature. 2006 Apr 20;440(7087):1045-9 [16625196.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:325-9 [4088306.001]
  • [Cites] Natl Cancer Inst Monogr. 1985 Dec;68:99-112 [4088315.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Lancet. 1994 Mar 19;343(8899):692-5 [7907678.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4277-80 [8044771.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2358-64 [7662982.001]
  • [Cites] Blood. 1996 Jul 15;88(2):682-9 [8695816.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1144-50 [9067285.001]
  • [Cites] Am J Hum Genet. 1998 Feb;62(2):334-45 [9463314.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1338-43 [9537225.001]
  • [Cites] Hum Genet. 2006 Jun;119(5):479-95 [16572268.001]
  • [Cites] J Cell Sci. 2006 Jun 15;119(Pt 12):2518-31 [16735446.001]
  • [Cites] PLoS Med. 2006 Jun;3(6):e168 [16671833.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Oncogene. 2006 Sep 14;25(41):5693-706 [16636668.001]
  • [Cites] J Cell Biol. 2006 Oct 9;175(1):55-66 [17030982.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1108-13 [17047656.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):105-17 [17259967.001]
  • [Cites] Cell. 1999 Dec 10;99(6):577-87 [10612394.001]
  • [Cites] Genes Dev. 2000 Apr 15;14(8):927-39 [10783165.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1400-6 [10837032.001]
  • [Cites] Leuk Res. 2000 Jul;24(7):553-8 [10867128.001]
  • [Cites] Cell. 2000 Jul 21;102(2):257-65 [10943845.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5548-52 [11034101.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):248-54 [11089982.001]
  • (PMID = 17683622.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein
  • [Number-of-references] 77
  • [Other-IDs] NLM/ PMC1959234
  •  go-up   go-down


97. Berz D, Freeman NJ: Extreme hyperlymphocytosis. J Clin Oncol; 2008 Feb 1;26(4):674-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Leukemia, Prolymphocytic, T-Cell / complications. Leukemia, Prolymphocytic, T-Cell / diagnosis. Lymphocytosis / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Syndrome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18235128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Zanesi N, Aqeilan R, Drusco A, Kaou M, Sevignani C, Costinean S, Bortesi L, La Rocca G, Koldovsky P, Volinia S, Mancini R, Calin G, Scott CP, Pekarsky Y, Croce CM: Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res; 2006 Jan 15;66(2):915-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
  • Chronic lymphocytic leukemia (CLL) is the most common leukemia in the world.
  • The TCL1 gene, responsible for prolymphocytic T cell leukemia, is also overexpressed in human B cell malignancies and overexpression of the Tcl1 protein occurs frequently in CLL.
  • Aging transgenic mice that overexpress TCL1 under control of the mu immunoglobulin gene enhancer, develop a CD5+ B cell lymphoproliferative disorder mimicking human CLL and implicating TCL1 in the pathogenesis of CLL.
  • This approach allowed us to verify the involvement of the Tcl1/Akt/mTOR biochemical pathway in the disease by testing the ability of a specific pharmacologic agent, rapamycin, to slow CLL.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Proto-Oncogene Proteins / genetics. Sirolimus / pharmacology
  • [MeSH-minor] Animals. Disease Models, Animal. Humans. Immunohistochemistry. Mice. Mice, Transgenic


99. Reiniger L, Bödör C, Bognár A, Balogh Z, Csomor J, Szepesi A, Kopper L, Matolcsy A: Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation. Leukemia; 2006 Jun;20(6):1089-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation.
  • Chronic lymphocytic leukemia (CLL) is an indolent B-cell non-Hodgkin's lymphoma that may transform into higher-grade lymphoma.
  • The transformation involves an increased number of prolymphocytic cells, termed prolymphocytic transformation (PLT) or the development of diffuse large B-cell lymphoma (DLBL), also referred to as Richter's transformation (RT).
  • To analyze whether activation-induced cytidine deaminase (AID), which is essential for somatic hypermutation (SHM) of normal B-cells, and malfunction of SHM termed aberrant somatic hypermutation (ASHM) are associated with higher-grade transformation of CLL, AID mRNA expression and the mutation pattern of c-MYC, PAX-5 and RhoH genes were analyzed in eight cases of CLL without transformation and in 21 cases that showed RT or PLT.
  • Chronic lymphocytic leukemia cases, which showed no transformation or eventually transformed into higher-grade lymphoma, showed low levels of AID mRNA expression and low frequency of mutations of c-MYC, PAX-5 and RhoH genes.
  • In both RT and PLT, high-levels of AID mRNA expression and high-frequency mutations of c-MYC, PAX-5 and RhoH genes were detected.
  • These results indicate that AID expression and ASHM are associated with higher-grade transformation of CLL and provide further evidences that AID expression and ASHM may be activated during the clonal history of B-cell lymphomas.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Cytidine Deaminase / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. RNA, Messenger / biosynthesis. Somatic Hypermutation, Immunoglobulin / genetics
  • [MeSH-minor] B-Cell-Specific Activator Protein / genetics. Gene Expression Profiling. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Mutation. Proto-Oncogene Proteins c-myc / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription Factors / genetics. rho GTP-Binding Proteins / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541139.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / PAX5 protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / RhoH protein, human; 0 / Transcription Factors; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


100. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res; 2006 Sep 1;12(17):5165-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits the mammalian target of rapamycin (mTOR), which regulates many aspects of cell growth and division.
  • RESULTS: Twenty-seven patients (9 acute myelogenous leukemia, 5 myelodysplastic syndrome, 6 B-chronic lymphocytic leukemia, 4 mantle cell lymphoma, 1 myelofibrosis, 1 natural killer cell/T-cell leukemia, and 1 T-cell prolymphocytic leukemia) received everolimus.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Prolymphocytic / drug therapy. Leukemia, T-Cell / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Myelodysplastic Syndromes / drug therapy. Sirolimus / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951235.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA55164
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; 9HW64Q8G6G / Everolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; W36ZG6FT64 / Sirolimus
  •  go-up   go-down






Advertisement